Document:

Exhibit 10.2

 

WARRANT

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE
FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

	No.
    SWK – CS – 1	December
    21, 2021

 

Biotricity
Inc.

 

Common
Stock Purchase Warrant

 

 

 

THIS
CERTIFIES THAT, for value received, SWK FUNDING LLC, or its registered assigns (the “Purchaser”), is entitled
to subscribe for and purchase from Biotricity Inc., a Nevada corporation (the “Company”), at any time commencing on
December 21, 2021, and expiring on December 21, 2028 (the “Warrant Exercise Term”), the Shares at the Exercise Price
(each as defined in Section 1 below).

 

This
Warrant is issued in connection Credit Agreement by and among the Company, as Borrower, the Purchaser, as Agent, and the financial institutions
party thereto from time to time as Lenders, dated as of even date herewith.

 

This
Warrant is subject to the following terms and conditions:

 

1.
Shares. The Purchaser has, subject to the terms set forth herein, the right to purchase, at any time during the Warrant Exercise
Term, up to 57,536 shares (the “Shares”) of the Company’s common stock, par value $0.001 (“Common Stock”),
at a per share exercise price of $6.26 (the “Exercise Price”). The Exercise Price is subject to adjustment as provided
in Section 3 hereof.

 

2.
Exercise of Warrant.

 

(a)
Exercise. This Warrant may be exercised by the Purchaser at any time during the Warrant Exercise Term, in whole or in part, by
delivering the notice of exercise attached as Exhibit A hereto (the “Notice of Exercise”), duly executed by
the Purchaser to the Company at its principal office, or at such other office as the Company may designate, accompanied by payment, in
cash or by wire transfer of immediately available funds or by check payable to the order of the Company, or via Cashless Exercise (as
defined below), of the amount obtained by multiplying the number of Shares designated in the Notice of Exercise by the Exercise Price
(the “Purchase Price”). For purposes hereof, “Exercise Date” shall mean the date on which all deliveries
required to be made to the Company upon exercise of this Warrant pursuant to this Section 2(a) shall have been made.

 

    	 

    	 

    

 

(b)
Cashless Exercise. In addition to the provisions of Section 2(a) above, the Purchaser may, in its sole discretion, exercise all
or any part of this Warrant in a “cashless” or “net-issue” exercise (a “Cashless Exercise”)
by delivering to the Company (1) the Notice of Exercise and (2) the original Warrant, pursuant to which the Purchaser shall surrender
the right to receive upon exercise of this Warrant the full number of Warrant Shares set forth in Section 1 hereof and instead, without
cash payment, shall receive a number of Warrant Shares calculated by using the following formula:

 

	 	X
    	=	Y
    (A - B)
	 	 	 	  A

 

	 	with:	X
    = 	the
    number of Warrant Shares to be issued to the Purchaser
	 	 	 	 
	 	 	Y
    =	the
    number of Warrant Shares with respect to which the Warrant is being exercised
	 	 	 	 
	 	 	A
    =	the
    fair value per share of Common Stock on the date of exercise of this Warrant
	 	 	 	 
	 	 	B
    =	the
    then-current Exercise Price of the Warrant

 

Solely
for the purposes of this paragraph 2(b), “fair value” per share of Common Stock shall mean (A) the average of the closing
sales prices, as quoted on the primary national or regional stock exchange on which the Common Stock is listed, or, if not listed, on
the Nasdaq Market if quoted thereon, on the twenty (20) consecutive Trading Days (as defined below) immediately preceding the date on
which the Notice of Exercise is deemed to have been sent to the Company, or (B) if the Common Stock is not publicly traded as set forth
above, as reasonably and in good faith determined by the Board of Directors of the Company as of the date which the Notice of Exercise
is deemed to have been sent to the Company.

 

For
purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued
in a cashless exercise transaction shall be deemed to have been acquired by the Purchaser, and the holding period for such shares shall
be deemed to have commenced, on the date this Warrant was originally issued.

 

(c)
Issuance of Certificates. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section
2(a) or 2(b) hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Purchaser (i) a certificate
or certificates for the number of validly issued, fully paid and non-assessable Shares to which the Purchaser shall be entitled upon
such exercise and, if applicable, (ii) a new warrant of like tenor to purchase all of the Shares that may be purchased pursuant to the
portion, if any, of this Warrant not exercised by the Purchaser. The Purchaser shall for all purposes hereof be deemed to have become
the Purchaser of record of such Shares on the date on which the Notice of Exercise and payment of the Purchase Price in accordance with
Section 2(a) or 2(b) hereof were delivered and made, respectively, irrespective of the date of delivery of such certificate or certificates,
except that if the date of such delivery, notice and payment is a date when the stock transfer books of the Company are closed, such
person shall be deemed to have become the holder of record of such Shares at the close of business on the next succeeding date on which
the stock transfer books are open. Warrant Shares purchased hereunder shall be transmitted by the transfer agent to the Purchaser by
crediting the account of the Purchaser’s prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian
system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Purchaser or (B) the shares are eligible
for resale by the Purchaser without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery to
the address specified by the Purchaser in the Notice of Exercise by the date that is three (3) Trading Days (as defined below) after
the latest of (A) the delivery to the Company of the Notice of Exercise and (B) surrender of this Warrant (if required). “Trading
Day” means a day on which the principal Trading Market is open for trading. “Trading Market” means any of
the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the
Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any
of the foregoing), the OTC Bulletin Board or OTC Markets, Inc.

 

    	2

    	 

    

 

(d)
Taxes. The issuance of the Shares upon the exercise of this Warrant, and the delivery of certificates or other instruments representing
such Shares, shall be made without charge to the Purchaser for any tax or other charge of whatever nature in respect of such issuance
and the Company shall bear any such taxes in respect of such issuance.

 

3.
Adjustment of Exercise Price and Number of Shares.

 

(a)
Adjustment for Reclassification, Consolidation or Merger. If while this Warrant, or any portion hereof, remains outstanding and
unexpired there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision
of shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other entity
in which the Company shall not be the surviving entity, or a reverse merger in which the Company shall be the surviving entity but the
shares of the Company’s capital stock outstanding immediately prior to the merger are converted by virtue of the merger into other
property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer of the Company’s properties and assets
as, or substantially as, an entirety to any other corporation or other entity in one transaction or a series of related transactions
(any of the events in (i) through (iii), a “Corporate Transaction”), then, as a part of such reorganization, recapitalization,
merger, consolidation, sale or transfer, unless otherwise directed by the Purchaser, all necessary or appropriate lawful provisions shall
be made so that the Purchaser shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified herein
and upon payment of the Exercise Price then in effect, the greatest number of shares of capital stock or other securities or property
that a holder of the Shares deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, recapitalization,
merger, consolidation, sale or transfer if this Warrant had been exercised immediately prior to such reorganization, recapitalization,
merger, consolidation, sale or transfer, all subject to further adjustment as provided in this Section 3. If the per share consideration
payable to the Purchaser for Shares in connection with any such transaction is in a form other than cash or marketable securities, then
the value of such consideration shall be determined in good faith by the Company’s Board of Directors (the “Board of Directors”).
The foregoing provisions of this paragraph shall similarly apply to successive reorganizations, recapitalizations, mergers, consolidations,
sales and transfers and to the capital stock or securities of any other corporation that are at the time receivable upon the exercise
of this Warrant. In all events, appropriate adjustment shall be made in the application of the provisions of this Warrant with respect
to the rights and interests of the Purchaser after the transaction, to the end that the provisions of this Warrant shall be applicable
after that event, as near as reasonably may be, in relation to any shares or other property deliverable or issuable after such reorganization,
recapitalization, merger, consolidation, sale or transfer upon exercise of this Warrant.

 

(b)
Adjustments for Split, Subdivision or Combination of Shares. If the Company shall at any time subdivide (by any stock split, stock
dividend, recapitalization, reorganization, reclassification or otherwise) the shares of Common Stock subject to acquisition hereunder,
then, after the date of record for effecting such subdivision, the Exercise Price in effect immediately prior to such subdivision will
be proportionately reduced and the number of shares of Common Stock subject to acquisition upon exercise of the Warrant will be proportionately
increased. If the Company at any time combines (by reverse stock split, recapitalization, reorganization, reclassification or otherwise)
the shares of Common Stock subject to acquisition hereunder, then, after the record date for effecting such combination, the Exercise
Price in effect immediately prior to such combination will be proportionately increased and the number of shares of Common Stock subject
to acquisition upon exercise of the Warrant will be proportionately decreased.

 

    	3

    	 

    

 

(c)
Adjustments for Dividends in Stock or Other Securities or Property. If while this Warrant, or any portion hereof, remains outstanding
and unexpired, the holders of any class of securities as to which purchase rights under this Warrant exist at the time shall have received
or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without
payment therefor, other or additional stock or other securities or property (other than cash) of the Company by way of dividend, then
and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of such class of security receivable
upon exercise of this Warrant, and without payment of any additional consideration therefor, the amount of such other or additional stock
or other securities or property (other than cash) of the Company that such holder would hold on the date of such exercise had it been
the holder of record of the class of security receivable upon exercise of this Warrant on the date hereof and had thereafter, during
the period from the date hereof to and including the date of such exercise, retained such shares and/or all other additional stock available
to it as aforesaid during said period, giving effect to all adjustments called for during such period by the provisions of this Section
3.

 

(d)
Notice of Adjustments. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Shares purchasable
upon the exercise of this Warrant, then, and in each such case, the Company, within 30 days thereafter, shall give written notice thereof
to the Purchaser at the address of such Purchaser as shown on the books of the Company, which notice shall state the Exercise Price as
adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of this Warrant, setting forth
in reasonable detail the method of calculation of each.

 

(e)
Notices Regarding Books Closure, Dividends, Subscription Offers and Certain Voting Rights. The Company will give written notice
to the Purchaser at least twenty (20) days prior to the date on which the Company closes its books or takes a record (A) with respect
to any dividend or distribution upon the Common Stock or (B) for determining rights to vote with respect to any Corporate Transaction,
dissolution or liquidation. Such written notice shall include a reasonable description of such Corporate Transaction, the expected date
of the consummation of such transaction or event, and the fair market value payable, as well as the number of Shares issuable upon exercise
of the Warrant if issued upon a Cashless Exercise pursuant to Section 2(b) in connection with such transaction or event. Without prejudice
to the foregoing, the Purchaser shall be entitled to the same rights to receive notice of all other corporate action as any holder of
Common Stock.

 

4.
Notices. All notices, requests, consents and other communications required or permitted under this Warrant shall be in writing
and shall be deemed delivered (i) three business days after being sent by registered or certified mail, return receipt requested, postage
prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business day
delivery or (iii) on the business day of delivery if send by facsimile transmission, in each case to the intended recipient as set forth
below:

 

If
to the Company to:

 

Biotricity
Inc.

275
Shoreline Drive, Suite 150

Redwood
City, California 94065

Attention:
Waqaas Al-Siddiq

E-Facsimile:
walsiddiq@biotricity.com

 

    	4

    	 

    

 

 

With
a copy (that shall not constitute notice) to:

 

Sichenzia Ross Ference LLP 

1185
Avenue of the Americas, 37th Floor 

New York, New York 10036 

Attention: David B. Manno, Esq. 

Facsimile: (212) 930-9725 

 

If
to the Purchaser to:

 

SWK
Funding LLC

14755
Preston Road, Suite 105

Dallas,
Texas 75254

Attention:
Winston Black

E-Facsimile:
wblack@swkhold.com

 

With
a copy (that shall not constitute notice) to:

 

Holland
& Knight LLP:

98
San Jacinto Boulevard, Suite 1900

Austin,
Texas 78701

Attention:
Paul W. Smith

Facsimile:
(512) 472-7473

 

Either
party may give any notice, request, consent or other communication under this Warrant using any other means (including personal delivery,
messenger service, facsimile transmission, first class mail or electronic mail), but no such notice, request, consent or other communication
shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Either party may
change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the other party
notice in the manner set forth in this Section 4.

 

5.
Legends. Each certificate evidencing the Shares issued upon exercise of this Warrant shall be stamped or imprinted with a legend
substantially in the following form:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE
FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

6.
Removal of Legend. Upon request of a holder of a certificate with the legends required by Section 5 hereof, the Company shall
issue to such holder a new certificate therefor free of any transfer legend, if, with such request, the Company shall have received an
opinion of counsel satisfactory to the Company in form and substance to the effect that any transfer by such holder of the Shares evidenced
by such certificate will not violate the Act or any applicable state securities laws.

 

    	5

    	 

    

 

7.
Fractional Shares. No fractional Shares will be issued in connection with any exercise hereunder. Instead, the Company shall round
up, as nearly as practicable to the nearest whole Share, the number of Shares to be issued. This Warrant may only be exercised for whole
shares.

 

8.
Rights of Stockholders. Except as expressly provided in Section 3(c) hereof, the Purchaser, as such, shall not be entitled to
vote or receive dividends or be deemed the holder of the Shares or any other securities of the Company that may at any time be issuable
on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Purchaser, as such, any of
the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders
at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock,
reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or
otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have been issued, as
provided herein.

 

9.
Registration Rights. In the event that the Company, at any time on or after January 15, 2021 and prior to the termination of this
Warrant, proposes to file on behalf of any stockholder or warrantholder of the Company a registration statement under the Act on any
form (other than a registration statement on Form S-4 or Form S-8) for shares or warrant shares held by any stockholder or warrantholder,
the Company shall provide written notice to the Purchaser as soon as practicable of such proposed filing, but in no event shall such
written notice be given to the Purchaser later than ten (10) days prior to the date that the Company intends to file such registration
statement, and, subject to the receipt by the Company of any information of the Purchaser reasonably required to be included in the registration
statement, the Purchaser shall have the right, in its discretion, to include the Shares of the Purchaser in such registration statement
at the Company’s expense; provided, however, that the Purchaser shall have no such right with respect to any Shares that cannot
be registered on such registration statement, as a result of the rules and regulations of the Securities and Exchange Commission. The
Purchaser shall not, in connection with any such registration, provide any information to the Company that contains any untrue statement
of a material fact or fail to state a material fact required to be stated or necessary to make the statements provided to the Company
not misleading, in light of the circumstances in which they were made.

 

10.
Miscellaneous.

 

(a)
This Warrant and disputes arising hereunder shall be governed by and construed and enforced in accordance with the laws of the State
of New York, without regard to its conflict of law rules.

 

(b)
The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

(c)
The covenants of the respective parties contained herein shall survive the execution and delivery of this Warrant.

 

(d)
The terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company
and of the Purchaser and of the Shares issued or issuable upon the exercise hereof.

 

(e)
This Warrant and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
parties with regard to the subject hereof.

 

(f)
The Company shall not, by amendment of the Certificate of Incorporation or Bylaws, or through any other means, directly or indirectly,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith assist
in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the
rights of the Purchaser contained herein against impairment.

 

(g)
Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to
the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at its expense, will
execute and deliver to the Purchaser, in lieu thereof, a new Warrant of like date and tenor.

 

(h)
This Warrant and any provision hereof may be amended, waived or terminated only by an instrument in writing signed by the Company and
the Purchaser.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS]

 

    	6

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be signed by its duly authorized officer.

 

	 	Biotricity
    Inc.
	 	 	 
	 	By:
    	 
	 	Name:
    	Waqaas
    Al-Siddiq
	 	Title:
    	Chief
    Executive Officer

 

    	7Exhibit
10.3

 

 

 

 

 

 

GUARANTEE
AND COLLATERAL AGREEMENT

 

dated
as of December 21, 2021

 

among

 

biotricity
inc.,

 

and
each other Person that becomes a party hereto as a grantor,

 

each
as a Grantor,

 

and

 

SWK
FUNDING LLC,

as Agent

 

 

 

 

 

 

    	 

     

    

 

GUARANTEE
AND COLLATERAL AGREEMENT

 

Guarantee
and Collateral Agreement, dated as of December 21, 2021
(as may be amended, restated, amended and restated, waived, supplemented, or otherwise modified from time to time, this “Agreement”),
made by each signatory hereto (together with any other Person that becomes a party hereto as provided herein, each individually a “Grantor”
and collectively, the “Grantors”), in favor of SWK Funding LLC, as
administrative and collateral agent (in such capacity, together with its successors and assigns, the “Agent”) for
the benefit of all Lenders party to the Credit Agreement (as hereafter defined).

 

Agent
and Lenders have severally agreed to extend credit to BIOTRICITY INC., a Nevada corporation (the “Borrower”), pursuant
to the Credit Agreement (as defined herein). Borrower is affiliated with each other Grantor. Borrower and the other Grantors are engaged
in interrelated businesses, and each Grantor will derive substantial direct and indirect benefit from extensions of credit under the
Credit Agreement. It is a condition precedent to each Lender’s obligation to extend credit under the Credit Agreement that Grantors
shall have executed and delivered this Agreement to Agent for the benefit of Agent and all Lenders.

 

In
consideration of the premises and to induce Agent and Lenders to enter into the Credit Agreement and to induce Agent and Lenders to extend
credit thereunder, each Grantor hereby agrees with Agent, for the benefit of Agent and all Lenders, as follows:

 

1.
Definitions.

 

1.1.
Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit
Agreement, and the following terms are used herein as defined in the Code (whether capitalized or lower case, plural or singular, as
applicable): Accounts, Money, Certificated Security, Chattel Paper, Commercial Tort Claims, Deposit Accounts, Documents, Electronic Chattel
Paper, Equipment, Farm Products, Goods, Health-Care-Insurance Receivables, Instruments, Inventory, Letter-of-Credit Rights, Software
and Supporting Obligations.

 

1.2.
When used herein the following terms shall have the following meanings:

 

“Agent”
has the meaning set forth in the preamble hereto.

 

“Agreement”
has the meaning set forth in the preamble hereto.

 

“Borrower
Obligations” means all Obligations of Borrower under and as defined in the Credit Agreement.

 

“Code”
means the Uniform Commercial Code as in effect from time to time in the State of New York; provided that, if perfection or the
effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial
Code as in effect in a jurisdiction other than the State of New York, “Code” means the Uniform Commercial Code (hereinafter
defined), as applicable if the context requires, as in effect from time to time in such other jurisdiction for purposes of the provisions
hereof relating to such perfection, effect of perfection or non-perfection or priority.

 

“Collateral”
has the meaning set forth in Section 3 hereof. Where the context requires, terms relating to the Collateral or any part thereof,
when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof.

 

    	1
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

“Copyright”
means all of Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right,
title, and interest in and to: (i) copyrights, rights and interests in copyrights, works protectable by copyright, all applications,
registrations and recordings related to the foregoing as may at any time be filed in the United States Copyright Office, or in any similar
office or agency of the United States, any State or Province thereof or any political subdivision thereof, or in any other country, and
all research and development relating to the foregoing; and (ii) all renewals of any of the foregoing.

 

“Copyright
Licenses” means all written agreements naming any Grantor as licensor or licensee, including those listed on Schedule 4,
granting any right under any Copyright, including the grant of rights to manufacture, distribute, exploit and sell materials derived
from any Copyright (other than agreements relating to widely-available software subject to “shrink-wrap” or “click-through”
software licenses).

 

“Credit
Agreement” means that certain Credit Agreement, of even date herewith, among Borrower, the financial institutions from time
to time party thereto (collectively, the “Lenders”) and Agent, as amended, supplemented, restated or otherwise modified
from time to time.

 

“Excluded
Property” means, with respect to a Grantor: (i) any item of General Intangibles or other property (including, without limitation,
any Material Contract) that is now or hereafter held by such Grantor but only to the extent that such item of General Intangibles or
property, including, for the avoidance of doubt, Intellectual Property (or any agreement evidencing such item of General Intangibles
or property) contains a term or is subject to a rule of law, statute or regulation that restricts, prohibits, or requires a consent (that
has not been obtained) of a Person (other than such Grantor) to, the creation, attachment or perfection of the security interest granted
herein, and any such restriction, prohibition and/or requirement of consent is effective and enforceable under applicable law and is
not rendered ineffective by applicable law (including, without limitation, pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the Code);
provided, however, that (x) Excluded Property shall not include any Proceeds of any item of General Intangibles or other property described
in this definition, and (y) any item of General Intangibles or such other property described in this definition that at any time ceases
to satisfy the criteria for Excluded Property (whether as a result of obtaining any necessary consent, any change in any rule of law,
statute or regulation, or otherwise) shall no longer be Excluded Property; (ii) Trademark applications filed in the United States Patent
and Trademark Office on the basis of such Grantor’s “intent to use” such Trademark, unless and until acceptable evidence
of use of the Trademark has been filed with the United States Patent and Trademark Office pursuant to Section 1(c) or Section 1(d) of
the Lanham Act (15 U.S.C. 1051, et seq.), to the extent that granting a Lien in such Trademark application prior to such filing would
adversely affect the enforceability or validity of such Trademark application; (iii) any asset subject to a Permitted Lien (other than
Liens in favor of Agent) securing obligations permitted under the Credit Agreement to the extent that the grant of other Liens on such
asset (A) would result in a breach or violation of, or constitute a default under, the agreement or instrument governing such Permitted
Lien, (B) would result in the loss of use of such asset or (C) would permit the holder of such Permitted Lien to terminate such Grantor’s
use of such asset; and (iv) assets if and for so long as, in the reasonable judgment of Agent in good faith consultation with Borrower,
the cost, adverse tax or regulatory costs or consequences, difficulty, burden or consequences of obtaining, perfecting or maintaining
a security interest in such assets exceeds the practical benefits to the Lenders afforded thereby.

 

“Fixtures”
means all of the following, whether now owned or hereafter acquired by a Grantor: plant fixtures; business fixtures; other fixtures and
storage facilities, wherever located; and all additions and accessories thereto and replacements therefor.

 

    	2
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

“General
Intangibles” means all “general intangibles” as such term is defined in Section 9-102(a)(42) of the Code and, in
any event, including with respect to any Grantor, all contracts, agreements, instruments and indentures in any form, and portions thereof,
to which such Grantor is a party or under which such Grantor has any right, title or interest or to which such Grantor or any property
of such Grantor is subject, as the same from time to time may be amended, supplemented or otherwise modified, including, without limitation,
(a) all rights of such Grantor to receive moneys due and to become due to it thereunder or in connection therewith, (b) all rights of
such Grantor to damages arising thereunder and (c) all rights of such Grantor to perform and to exercise all remedies thereunder.

 

“Guarantor
Obligations” means, collectively, with respect to each Guarantor, all payment and performance obligations of such Guarantor
hereunder or under any other Loan Document to which such Guarantor is party.

 

“Guarantors”
means the collective reference to each Grantor other than Borrower.

 

“Identified
Claims” means the Commercial Tort Claims described on Schedule 6 as such schedule may be supplemented from time to time.

 

“Intellectual
Property” shall mean all present and future: trade secrets, know-how and other proprietary information; Trademarks and Trademark
Licenses, internet domain names, service marks, trade dress, trade names, business names, designs, logos, slogans (and all translations,
adaptations, derivations and combinations of the foregoing) indicia and other source and/or business identifiers, and the goodwill of
the business relating thereto and all registrations or applications for registrations which have heretofore been or may hereafter be
issued thereon throughout the world; Copyrights (including Copyrights for computer programs, but excluding commercially available off-the-shelf
software and any Intellectual Property rights relating thereto) and Copyright Licenses, and all tangible and intangible property embodying
the Copyrights, unpatented inventions (whether or not patentable); Patents and Patent Licenses; Mask Works; industrial design applications
and registered industrial designs; license agreements related to any of the foregoing and income therefrom, books, records, writings,
computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases
and other physical manifestations, embodiments or incorporations of any of the foregoing; customer lists and customer information, the
right to sue for all past, present and future infringements of any of the foregoing; all other intellectual property; and all common
law and other rights throughout the world in and to all of the foregoing.

 

“Intercompany
Note” means any promissory note evidencing loans made by any Grantor to any other Grantor or its Affiliate.

 

“Investment
Property” means the collective reference to (a) all “investment property” as such term is defined in Section 9-102(a)(49)
of the Code (other than the equity interest of any Subsidiary excluded from the definition of Pledged Equity), (b) all “financial
assets” as such term is defined in Section 8-102(a)(9) of the Code, and (c) whether or not constituting “investment property”
as so defined, all Pledged Notes and all Pledged Equity.

 

“Issuers”
means the collective reference to each issuer of any Investment Property.

 

“Mask
Works” means all of any Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter
acquired right, title, and interest in and to mask works or similar rights available for the protection of semiconductor chips.

 

“Patent”
means all of Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right,
title and interest in and to: (i) all patents, patent applications, inventions, invention disclosures and improvements, and all applications,
registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office,
or in any similar office or agency of the United States, any State or Province thereof or any political subdivision thereof, or in any
other country or multi-jurisdictional patent office or agency, and all research and development relating to the foregoing; and (ii) the
reissues, divisions, continuations, renewals, re-examinations, extensions and continuations-in-part of any of the foregoing.

 

    	3
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

“Patent
Licenses” means all agreements, whether written or oral, providing for the grant by or to any Grantor of any right to manufacture,
use or sell any invention covered in whole or in part by a Patent, including any of the foregoing referred to in Schedule 4.

 

“Permitted
Liens” has the meaning ascribed such term in the Credit Agreement.

 

“Pledged
Equity” means the equity interests listed on Schedule 1, as amended from time to time, together with any other equity
interests, certificates, options or rights of any nature whatsoever in respect of the equity interests of any Person that may be issued
or granted to, or held by, Grantor while this Agreement is in effect. [TBD Based on Final Org Chart]

 

“Pledged
Notes” means all promissory notes listed on Schedule 1, all Intercompany Notes at any time issued to any Grantor and
all other promissory notes issued to or held by any Grantor (other than promissory notes issued in connection with extensions of trade
credit by any Grantor in the ordinary course of business).

 

“Proceeds”
means all “proceeds” as such term is defined in Section 9-102(a)(64) of the Code and, in any event, shall include all dividends
or other income from the Investment Property, collections thereon or distributions or payments with respect thereto.

 

“Receivable”
means any right to payment for goods sold or leased or for services rendered, whether or not such right is evidenced by an Instrument
or Chattel Paper and whether or not it has been earned by performance (including any Accounts).

 

“Secured
Obligations” means, collectively, all Borrower Obligations and Guarantor Obligations.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Trademark”
means all of Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right,
title, and interest in and to: (i) all of Grantor’s (or if referring to another Person, such other Person’s) trademarks,
trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos, other business
identifiers, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the united States
Patent and Trademark, or in any similar office or agency of the United States, any State or Province thereof or any political subdivision
thereof, or in any other country, and all research and development and goodwill of the business relating thereto; (ii) all renewals thereof;
and (iii) all designs and general intangibles of a like nature.

 

“Trademark
Licenses” means, collectively, each agreement, whether written or oral, providing for the grant by or to any Grantor of any
right to use any Trademark, including any of the foregoing referred to in Schedule 4.

 

    	4
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

2.
Guarantee.

 

2.1.
Guarantee.

 

(a)
Each of the Guarantors hereby, jointly and severally, unconditionally and irrevocably, guarantees to Agent, for the benefit of Agent
and Lenders and their respective successors, indorsees, transfers and assigns to the extent permitted by and in accordance with the Credit
Agreement, the prompt and complete payment and performance by Borrower when due (whether at the stated maturity, by acceleration or otherwise)
of Borrower Obligations.

 

(b)
The guarantee contained in this Section 2 shall remain in full force and effect and shall serve as a continuing security, until
all of the Secured Obligations have been Paid in Full.

 

(c)
No payment made by Borrower, any of the Guarantors, any other guarantor or any other Person or received or collected by Agent or any
Lender from Borrower, any of the Guarantors, any other guarantor or any other Person by virtue of any action or proceeding or any set-off
or appropriation or application at any time or from time to time in reduction of or in payment of the Secured Obligations shall be deemed
to modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall, notwithstanding any such payment
(other than any payment made by such Guarantor in respect of the Secured Obligations or any payment received or collected from such Guarantor
in respect of the Secured Obligations), remain liable for the Secured Obligations up to the maximum liability of such Guarantor hereunder
until the Secured Obligations are Paid in Full.

 

2.2.
Right of Contribution. Each Guarantor hereby agrees that to the extent that a Guarantor shall have paid more than its proportionate
share of any payment made hereunder, such Guarantor shall be entitled to seek and receive contribution from and against any other Guarantor
hereunder which has not paid its proportionate share of such payment. Each Guarantor’s right of contribution shall be subject to
the terms and conditions of Section 2.3. The provisions of this Section 2.2 shall in no respect limit the obligations and
liabilities of any Guarantor to Agent and Lenders, and each Guarantor shall remain liable to Agent and Lenders for the full amount guaranteed
by such Guarantor hereunder.

 

2.3.
No Subrogation. Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any Guarantor
by Agent or any Lender, no Guarantor shall be entitled to be subrogated to any of the rights of Agent or any Lender against Borrower
or any other Guarantor or any collateral security or guarantee or right of offset held by Agent or any Lender for the payment of the
Secured Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from Borrower or any other
Guarantor in respect of payments made by such Guarantor hereunder, until all of the Secured Obligations are Paid in Full; provided,
however, that each Guarantor agrees that such right of subrogation shall be automatically (without any further action) and irrevocably
waived and released in its entirety if any Collateral is acquired by a Person as a result of the exercise of remedies under the Loan
Documents, a court order or a plan of reorganization or similar dispositive plan. If any amount shall be paid to any Guarantor on account
of such subrogation rights at any time when all of the Secured Obligations shall not have been Paid in Full (or when such right of subrogation
shall have been waived), such amount shall be held by such Guarantor in trust for Agent and Lenders, segregated from other funds of such
Guarantor, and shall, forthwith upon receipt by such Guarantor, be promptly turned over to Agent in the exact form received by such Guarantor
(duly indorsed (but without any representation or warranty) by such Guarantor to Agent, if required), to be applied against the Secured
Obligations, whether matured or unmatured, in a manner that is consistent with the provisions of Section 2.10.2 of the Credit
Agreement.

 

    	5
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

2.4.
Amendments, etc. with Respect to the Secured Obligations. Each Guarantor shall remain obligated hereunder notwithstanding that,
without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, any demand for payment
of any of the Secured Obligations made by Agent or any Lender may be rescinded by Agent or such Lender and any of the Secured Obligations
continued, and the Secured Obligations, or the liability of any other Person upon or for any part thereof, or any collateral security
or guarantee therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended,
modified, accelerated, compromised, waived, surrendered or released by Agent or any Lender, and the Credit Agreement and the other Loan
Documents and any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated,
in whole or in part, as Agent (or the Required Lenders or all Lenders, as the case may be) may deem advisable from time to time (provided
that any such amendment, modification, supplement or termination complies with the relevant provisions of the Credit Agreement, this
Agreement and/or such other Loan Document), and any collateral security, guarantee or right of offset at any time held by Agent or any
Lender for the payment of the Secured Obligations may be sold, exchanged, waived, surrendered or released to the extent permitted by
the Credit Agreement, this Agreement and the other Loan Documents. Neither Agent nor any Lender shall have any obligation to protect,
secure, perfect or insure any Lien at any time held by it as security for the Secured Obligations or for the guarantee contained in this
Section 2 or any property subject thereto.

 

2.5.
Guarantee Absolute and Unconditional; Waivers.

 

(a)
Each Guarantor agrees that this Agreement is a guarantee of payment and performance when due and not of collectability. The liability
of Guarantors under this Agreement shall be absolute, irrevocable and unconditional irrespective of:

 

(i)
any lack of validity, regularity or enforceability of any Loan Document;

 

(ii)
any lack of validity, regularity or enforceability of this Agreement;

 

(iii)
any change in the time, manner or place of payment of, or in any other term of, all or any of the Secured Obligations, or any other amendment
or waiver of or any consent to departure from any Loan Document;

 

(iv)
any exchange, release or non-perfection of any security interest in any Collateral, or any release or amendment or waiver of or consent
to departure from any other guarantee, for all or any of the Secured Obligations;

 

(v)
any failure on the part of Agent or any other Person to exercise, or any delay in exercising, any right under any Loan Document; and

 

(vi)
any other circumstance which might otherwise constitute a defense available to, or a discharge of, Borrower, any Guarantor or any other
guarantor with respect to the Secured Obligations (including, without limitation, all defenses based on suretyship or impairment of collateral,
and all defenses that Borrower may assert to the repayment of the Secured Obligations, including, without limitation, failure of consideration,
breach of warranty, payment, statute of frauds, bankruptcy, lack of legal capacity, lender liability, accord and satisfaction, and usury),
this Agreement and the obligations of Guarantors under this Agreement, other than Payment in Full of the Guarantor Obligations.

 

    	6
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(b)
Each Guarantor hereby agrees that if Borrower or any other guarantor of all or a portion of the Secured Obligations is the subject of
a bankruptcy or insolvency case under applicable law, it will not assert the pendency of such case or any order entered therein as a
defense to the timely payment of the Secured Obligations. Each Guarantor waives any and all notice of the creation, renewal, extension
or accrual of any of the Secured Obligations and notice of or proof of reliance by Agent or any Lender upon the guarantee contained in
this Section 2 or acceptance of the guarantee contained in this Section 2; the Secured Obligations, and any of them, shall
conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guarantee
contained in this Section 2, and all dealings between Borrower and any of the Guarantors, on the one hand, and Agent and Lenders,
on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guarantee contained in
this Section 2. Each Guarantor waives (i) diligence, presentment, protest, demand for payment and notice of default or nonpayment
to or upon Borrower or any of the Guarantors with respect to the Secured Obligations; (ii) notice of the existence or creation or renewal
or non-payment of all or any of the Secured Obligations; (iii) all diligence in collection or protection of or realization upon any Secured
Obligations or any security for or guarantee of any Secured Obligations; (iv) any right to require Agent or any Lender, as a condition
of payment or performance by Guarantor, to (A) proceed against Borrower, any other guarantor of the Guarantor Obligations or any other
Person, (B) proceed against or exhaust any security held from Borrower, any such other guarantor or any other Person, (C) proceed against
or have resort to any balance of any deposit account or credit on the books of Agent or any Lender in favor of Borrower or any other
Person or (D) pursue any other remedy in the power of Agent or any Lender whatsoever; (v) any defense arising by reason of the incapacity,
lack of authority or any disability or other defense of Borrower or any other Guarantor including any defense based on or arising out
of the lack of validity or the unenforceability of the Guarantor Obligations or any agreement or instrument relating thereto or by reason
of the cessation of the liability of Borrower or any other Guarantor from any cause other than payment in full of the Guarantor Obligations;
(vi) any defense based upon Agent or any Lender’s errors or omissions in the administration of the Guarantor Obligations, except
errors and omissions resulting from Agent or any Lender’s gross negligence or willful misconduct as determined by a court of competent
jurisdiction in a non-appealable order and (vii) (A) any legal or equitable discharge of Guarantor’s obligations hereunder and
(B) any rights to set-offs, recoupments and counterclaims.

 

(c)
When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Guarantor, Agent or any Lender may,
but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as it may have against Borrower,
any other Guarantor or any other Person or against any collateral security or guarantee for the Secured Obligations or any right of offset
with respect thereto, and any failure by Agent or any Lender to make any such demand, to pursue such other rights or remedies or to collect
any payments from Borrower, any other Guarantor or any other Person or to realize upon any such collateral security or guarantee or to
exercise any such right of offset, or any release of Borrower, any other Guarantor or any other Person or any such collateral security,
guarantee or right of offset, shall not relieve any Guarantor of any obligation or liability hereunder, and shall not impair or affect
the rights and remedies, whether express, implied or available as a matter of law, of Agent or any Lender against any Guarantor. For
the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings. Each Guarantor agrees
that it is not a surety for purposes of any state statutes providing defenses for sureties, and each Guarantor waives any right that
it may have under such statutes to assert the applicability thereof to the provisions of this Agreement to require that Agent commence
action against Borrower or any other Person or against any of the Collateral.

 

(d)
Agent or any Lender may, from time to time, at its sole discretion and without notice to any Guarantor, take any or all of the following
actions: (i) retain or obtain a security interest in any property to secure any of the Secured Obligations or any obligation hereunder,
(ii) retain or obtain the primary or secondary obligation of any obligor or obligors with respect to any of the Secured Obligations,
(iii) extend or renew any of the Secured Obligations for one or more periods (whether or not longer than the original period), alter
or exchange any of the Secured Obligations, or release or compromise any obligation of any Guarantor or any obligation of any nature
of any other obligor with respect to any of the Secured Obligations, (iv) release any guarantee or right of offset or its security interest
in, or surrender, release or permit any substitution or exchange for, all or any part of any property securing any of the Secured Obligations
or any obligation hereunder, or extend or renew for one or more periods (whether or not longer than the original period) or release,
compromise, alter or exchange any obligations of any nature of any obligor with respect to any such property, and (v) resort to any Guarantor
for payment of any of the Secured Obligations when due, whether or not Agent or such Lender shall have resorted to any property securing
any of the Secured Obligations or any obligation hereunder or shall have proceeded against any other Guarantor or any other obligor primarily
or secondarily obligated with respect to any of the Secured Obligations.

 

    	7
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

2.6.
Payments. Each Guarantor hereby guarantees that payments hereunder will be paid to Agent without set-off or counterclaim in Dollars
at the office of Agent specified in the Credit Agreement.

 

2.7.
Joint and Several Liability of Guarantors

 

(a)
Each Guarantor is accepting joint and several liability hereunder and under the other Loan Documents in consideration of the financial
accommodations to be provided by the Lenders under the Credit Agreement, for the mutual benefit, directly and indirectly, of each Guarantor
and in consideration of the undertakings of the other Guarantors to accept joint and several liability for the Obligations.

 

(b)
Each Guarantor, jointly and severally, hereby irrevocably and unconditionally accepts, not merely as a surety but also as a co-debtor,
joint and several liability with the other Guarantors, with respect to the payment and performance of all of the Obligations (including,
without limitation, any Obligations arising under this Section 2.7), it being the intention of the parties hereto that all the
Obligations shall be the joint and several obligations of each Guarantor without preferences or distinction among them.

 

(c)
If and to the extent that any Guarantor shall fail to make any payment with respect to any of the Obligations as and when due or to perform
any of the Obligations in accordance with the terms thereof, then in each such event the other Guarantors will make such payment with
respect to, or perform, such Obligation until such time as all of the Obligations are Paid in Full.

 

(d)
The Obligations of each Guarantor under the provisions of this Section 2.7 constitute the absolute and unconditional, full recourse
Obligations of each Guarantor enforceable against each Guarantor to the full extent of its property and assets charged hereunder, irrespective
of the validity, regularity or enforceability of this Agreement or any other circumstances whatsoever, except as enforceability may be
limited by bankruptcy, insolvency, fraudulent conveyance or similar laws affecting creditors’ rights generally and general principles
of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law).

 

(e)
Except as otherwise expressly provided in this Agreement, each Guarantor hereby waives, to the fullest extent permitted by applicable
law, notice of acceptance of its joint and several liability, notice of any borrowing or any disbursement from any escrow account, notice
of the occurrence of any Default, Event of Default, or of any demand for any payment under this Agreement or any other Loan Document,
notice of any action at any time taken or omitted by the Agent of any of the Obligations, any requirement of diligence or to mitigate
damages and, generally, to the fullest extent permitted by applicable law, all demands, notices and other formalities of every kind in
connection with this Agreement (except as otherwise provided in this Agreement). Each Guarantor hereby assents to, and waives, to the
extent permitted by law, notice of, any extension or postponement of the time for the payment of any of the Obligations, the acceptance
of any payment of any of the Obligations, the acceptance of any partial payment thereon, any waiver, consent or other action or acquiescence
by the Agent or the Lenders at any time or times in respect of any default by any Guarantor or any other Loan Party in the performance
or satisfaction of any term, covenant, condition or provision of this Agreement, any and all other indulgences whatsoever by the Agent
or the Lenders in respect of any of the Obligations, and the taking, addition, substitution or release, in whole or in part, at any time
or times, of any security for any of the Obligations or the addition, substitution or release, in whole or in part, of any Guarantor
or any other Loan Party. Without limiting the generality of the foregoing, each Guarantor assents to any other action or delay in acting
or failure to act on the part of the Agent or any Lender with respect to the failure by any Guarantor or any other Loan Party to comply
with any of its respective Obligations, including, without limitation, any failure strictly or diligently to assert any right or to pursue
any remedy or to comply fully with applicable laws or regulations thereunder, which might, but for the provisions of this Section
2.7 afford grounds for terminating, discharging or relieving any Guarantor, in whole or in part, from any of its Obligations under
this Section 2.7, it being the intention of each Guarantor that, so long as any of the Obligations hereunder remain unsatisfied,
the Obligations of each Guarantor under this Section 2.7 shall not be discharged except by performance and then only to the extent
of such performance. The Obligations of each Guarantor under this Section 2.7 shall not be diminished or rendered unenforceable
by any winding up, reorganization, arrangement, liquidation, reconstruction or similar proceeding with respect to Loan Party or the Agent
or any Lender.

 

    	8
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(f)
Each Guarantor is obligated to repay the Obligations as a joint and several obligor under this Agreement and the other Loan Documents.
To the extent that any Guarantor shall, under this Agreement as a joint and several obligor, repay any of the Obligations constituting
Loans made to another Grantor hereunder or other Obligations incurred directly and primarily by any other Guarantor (an “Accommodation
Payment”), then the Guarantor making such Accommodation Payment shall be entitled to contribution and indemnification from,
and be reimbursed by, each of the other Guarantors in an amount, for each of such other Guarantors, equal to a fraction of such Accommodation
Payment, the numerator of which fraction is such other Guarantor’s Allocable Amount and the denominator of which is the sum of
the Allocable Amounts of all of the Guarantors. As of any date of determination, the “Allocable Amount” of each Guarantor
shall be equal to the maximum amount of liability for Accommodation Payments which could be asserted against such Guarantor hereunder
without (i) rendering such Guarantor “insolvent” within the meaning of Section 101(31) of the Bankruptcy Code, Section 2
of the Uniform Fraudulent Transfer Act or Section 2 of the Uniform Fraudulent Conveyance Act, (ii) leaving such Guarantor with unreasonably
small capital or assets, within the meaning of Section 548 of the Bankruptcy Code, Section 4 of the Uniform Fraudulent Transfer Act or
Section 5 of the Uniform Fraudulent Conveyance Act, or (iii) leaving such Guarantor unable to pay its debts as they become due within
the meaning of Section 548 of the Bankruptcy Code, Section 4 of the Uniform Fraudulent Transfer Act or Section 5 of the Uniform Fraudulent
Conveyance Act. All rights and claims of contribution, indemnification, and reimbursement under this Section 2.7(f) shall be subordinate
in right of payment to the prior indefeasible Payment in Full of the Obligations. The provisions of this Section 2.7(f) shall,
to the extent inconsistent with any provision in any Loan Document, supersede such inconsistent provision.

 

(g)
Each Guarantor represents and warrants to the Agent and the Lenders that as of the date hereof such Guarantor is currently informed of
the financial condition of each Loan Party and of all other circumstances which a diligent inquiry would reveal and which bear upon the
risk of nonpayment of the Obligations. Each Guarantor further represents and warrants to the Agent and the Lenders that such Guarantor
has read and understands the terms and conditions of the Loan Documents. Each Guarantor hereby covenants that such Guarantor will continue
to keep informed of Guarantors’ financial condition, and of all other circumstances which bear upon the risk of nonpayment or nonperformance
of the Obligations.

 

(h)
The provisions of this Section 2.7 are made for the benefit of the Agent, the Lenders and their respective successors and assigns,
and may be enforced by it or them from time to time against any or all Guarantors as often as occasion therefor may arise and without
requirement on the part of the Agent, such Lender, successor or assign first to marshal any of its or their claims or to exercise any
of its or their rights against any Guarantor or to exhaust any remedies available to it or them against any Guarantor or any other Loan
Party or to resort to any other source or means of obtaining payment of any of the Obligations hereunder or to elect any other remedy.
The provisions of this Section 2.7 shall remain in effect until all of the Obligations shall have been Paid in Full. If at any
time, any payment, or any part thereof, made in respect of any of the Obligations, is rescinded or must otherwise be restored or returned
by the Agent or any Lender upon the insolvency, bankruptcy or reorganization of any Guarantor, or otherwise, the provisions of this Section
2.7 will forthwith be reinstated in effect, as though such payment had not been made.

 

    	9
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(i)
Each Guarantor hereby agrees that it will not enforce any of its rights of contribution or subrogation against any other Guarantor with
respect to any liability incurred by it hereunder or under any of the other Loan Documents, any payments made by it to the Agent or the
Lenders with respect to any of the Obligations or any collateral security therefor until such time as all of the Obligations have been
Paid in Full. Any claim which any Guarantor may have against any other Guarantor with respect to any payments to the Agent or any Lender
hereunder or under any other Loan Documents are hereby expressly made subordinate and junior in right of payment, without limitation
as to any increases in the Obligations arising hereunder or thereunder, to the Obligations having been Paid in Full and, in the event
of any insolvency, bankruptcy, receivership, liquidation, reorganization or other similar proceeding under the laws of any jurisdiction
relating to any Guarantor, its debts or its assets, whether voluntary or involuntary, all such Obligations shall be Paid in Full before
any payment or distribution of any character, whether in cash, securities or other property, shall be made to any other Guarantor therefor.

 

(j)
Each Guarantor hereby agrees that, after the occurrence and during the continuance of any Event of Default, the payment of any amounts
due with respect to the indebtedness owing by any Guarantor to any other Guarantor is hereby subordinated to the Obligations having been
Paid in Full. Each Guarantor hereby agrees that after the occurrence and during the continuance of any Event of Default, such Guarantor
will not demand, sue for or otherwise attempt to collect any indebtedness of any other Guarantor owing to such Guarantor until the Obligations
shall have been Paid in Full. If, notwithstanding the foregoing sentence, such Guarantor shall collect, enforce or receive any amounts
in respect of such indebtedness, such amounts shall be collected, enforced and received by such Guarantor in trust for the Agent and
Lenders, and such Guarantor shall deliver any such amounts to the Agent for application to the Obligations in accordance with Section
2.10.2 of the Credit Agreement.

 

3.
Grant of Security Interest.

 

(a)
Each Grantor hereby assigns and transfers to Agent, and hereby grants to Agent, for the benefit of Agent and Lenders and (to the extent
provided herein) their Affiliates, a security interest in all of the following (if applicable):

 

(i)
all of Grantor’s right, title and interest in and to all of such Grantor’s assets, including any and all personal property,
Accounts, Chattel Paper (including Electronic Chattel Paper), Deposit Accounts, Documents, Equipment, Farm Products, Fixtures, General
Intangibles, Goods, Health-Care-Insurance Receivables, Instruments, Intellectual Property, Inventory, Investment Property, Letter-of-Credit
Rights, Software, Money, Supporting Obligations, and Identified Claims, in each case whether now owned or at any time hereafter acquired
or arising,

 

(ii)
all books and records pertaining to any of the foregoing,

 

(iii)
all Proceeds and products of any of the foregoing, and

 

(iv)
all collateral security and guarantees given by any Person with respect to any of the foregoing,

 

    	10
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(all
of the foregoing, collectively, the “Collateral”), as collateral security for the prompt and complete payment and
performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations; provided, that
the Collateral shall not include the Excluded Property.

 

(b)
Each Grantor shall promptly notify Agent of any Commercial Tort Claims related to the Loans in which such Grantor has an interest arising
after the Closing Date and shall provide all necessary information concerning each such Commercial Tort Claim and make all necessary
filings with respect thereto to perfect Agent’s first-priority security interest (subject to Permitted Liens) therein.

 

(c)
Each Grantor has full right and power to grant to Agent, for the benefit of Agent and Lenders, a perfected, first-priority security interest
(subject to Permitted Liens) and Lien on the Collateral pursuant to this Agreement, subject to no transfer or other restrictions or Liens
of any kind in favor of any other Person (subject to any Permitted Liens). Except with respect to any financing statement (i) securing
debt to be paid off as of the Closing Date, (ii) securing Permitted Liens, or (iii) filed on behalf of Agent, no financing statement
relating to any of the Collateral is on file in any public office. No Grantor is party to any agreement, document or instruction that
conflicts with this Section 3.

 

(d)
Each Grantor hereby authorizes Agent to prepare and file financing statements provided for by the Code, or any similar law in any other
jurisdiction, and to take such other action as may be required, in Agent’s sole discretion, to perfect and to continue the perfection
of Agent’s security interest in the Collateral.

 

(e)
Irrespective of any provision in this Agreement, the prior consent of Agent shall not be required in connection with the licensing or
sublicensing of Intellectual Property pursuant to collaborations, licenses or other strategic transactions with third parties (“Permitted
Licenses”) executed in the normal course of Borrower’s business and excluding, for the avoidance of doubt, any exclusive
license or sublicense.

 

4.
Representations and Warranties.

 

To
induce Agent and Lenders to enter into the Credit Agreement and to induce Lenders to make their respective extensions of credit to Borrower
thereunder, each Grantor jointly and severally hereby represents and warrants to Agent and each Lender that:

 

4.1.
Title; No Other Liens. Except for Permitted Liens, the Grantors own each item of the Collateral, tangible and intangible, of any
nature whatsoever that they purport to own free and clear of any and all Liens or claims of others (including infringement claims with
respect to Intellectual Property). As of the Closing Date (or the date such Grantor joins this Agreement as it relates to such Grantor),
no financing statement or other public notice with respect to all or any part of the Collateral is on file or of record in any public
office, except filings evidencing Permitted Liens and filings for which termination statements have been delivered to Agent.

 

4.2.
Perfected First Priority Liens. Each Grantor has full right and power to grant to Agent the security interests contemplated herein,
and the security interests granted pursuant to this Agreement are prior and senior to all other Liens on the Collateral in existence
on the date hereof except for Permitted Liens expressly permitted by the Credit Agreement.

 

4.3.
Grantor Information. Schedule 2 sets forth, as of the Closing Date (or the date such Grantor joins this Agreement as it
relates to such Grantor), (a) each Grantor’s jurisdiction of organization, (b) the location of each Grantor’s chief executive
office, (c) each Grantor’s exact legal name as it appears on its organizational documents, (d) each Grantor’s federal business
or tax identification number, and (e) each Grantor’s organizational identification number.

 

    	11
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

4.4.
Collateral Locations. Schedule 3 sets forth, as of the Closing Date (or the date such Grantor joins this Agreement as it
relates to such Grantor), (a) each place of business of each Grantor (including its chief executive office), (b) all locations where
all Inventory and the Equipment owned by each Grantor is kept, and (c) whether each such Collateral location and place of business (including
each Grantor’s chief executive office) is owned or leased (and if leased, specifies the complete name and notice address of each
lessor as set forth in the relevant lease). No Collateral is located outside the United States or in the possession of any lessor, bailee,
warehouseman or consignee, except as indicated on Schedule 3.

 

4.5.
Certain Property. Except as set forth on Schedule 8, none of the Collateral constitutes, or is the Proceeds of, (a) Farm
Products, (b) Health-Care-Insurance Receivables or (c) vessels, aircraft or any other property subject to any certificate of title or
other registration statute of the United States, any state or other jurisdiction, except for personal vehicles owned by the Grantors
and used by employees of the Grantors in the ordinary course of business.

 

4.6.
Investment Property.

 

(a)
The shares of Pledged Equity pledged by each Grantor hereunder constitute all the issued and outstanding equity interests of each Issuer
owned by such Grantor. The Pledged Equity is not classified as, and each Grantor hereby agrees that it shall take no action to classify
any Pledged Equity as, certificated securities under the terms of Article 8 of the Code.

 

(b)
All of the Pledged Equity issued by a Subsidiary of each Grantor has been duly and validly issued and is fully paid and nonassessable.

 

(c)
Each of the Pledged Notes (if any) constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable
in accordance with its terms (subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and
other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a
proceeding in equity or at law) and an implied covenant of good faith and fair dealing).

 

(d)
Schedule 1 lists all Investment Property owned by each Grantor as of the Closing Date (or the date such Grantor joins this Agreement
as it relates to such Grantor). Each Grantor is the record and beneficial owner of the Investment Property pledged by it hereunder that
it purports to own, free of any and all Liens or options in favor of, or claims of, any other Person, except the security interest created
by this Agreement and for Permitted Liens.

 

4.7.
Receivables.

 

(a)
No amount payable to such Grantor under or in connection with any Receivable is evidenced by any Instrument or Chattel Paper which has
not been delivered to Agent.

 

(b)
The amounts represented by such Grantor to Lenders from time to time as owing to such Grantor in respect of the Receivables (to the extent
such representations are required by any of the Loan Documents) will at all such times be accurate in all material respects, subject
to the inability to collect Receivables in the ordinary course of business.

 

    	12
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

4.8.
Intellectual Property.

 

(a)
Schedule 4 lists all Intellectual Property owned or leased by each Grantor in its own name (or a former name) on the Closing Date
(or the date such Grantor joins this Agreement as it relates to such Grantor).

 

(b)
On the Closing Date (or the date such Grantor joins this Agreement as it relates to such Grantor), all Intellectual Property pledged
as Collateral is valid, subsisting, unexpired and enforceable, has not been abandoned and, to Grantor’s knowledge, does not infringe
on the intellectual property rights of any other Person.

 

(c)
Except as set forth in Schedule 4, as of the Closing Date (or the date such Grantor joins this Agreement as it relates to such
Grantor), none of the Intellectual Property pledged as Collateral is the subject of any licensing or franchise agreement pursuant to
which any Grantor is the licensor or franchisor.

 

(d)
Except as set forth in Schedule 4, no holding, decision or judgment has been rendered by any Governmental Authority which would
limit, cancel or question the validity of, or any Grantor’s rights in, any Intellectual Property pledged as Collateral.

 

(e)
Except as set forth in Schedule 4, no action or proceeding is pending, or, to the knowledge of any Grantor, is threatened, as
of the Closing Date (or the date such Grantor joins this Agreement as it relates to such Grantor) (i) seeking to limit, cancel or question
the validity of any Intellectual Property pledged as Collateral or any Grantor’s interest therein, or (ii) which, if adversely
determined, would materially and adversely affect the value of any Intellectual Property pledged as Collateral.

 

(f)
Each Grantor owns and possesses or has a license or other right to use all Intellectual Property pledged as Collateral as is necessary
for the conduct of the businesses of such Grantor as currently conducted, without any infringement, to such Grantor’s knowledge,
upon rights of others.

 

4.9.
Deposit Accounts and Other Accounts. All Deposit Accounts and all other bank accounts, securities accounts and other accounts
maintained by each Grantor as of the Closing Date (or the date such Grantor joins this Agreement as it relates to such Grantor), are
described on Schedule 5 hereto, which description includes for each such account the name of such Grantor maintaining such account,
the name, address, telephone and fax numbers of the financial institution at which such account is maintained, and the account number
and the account officer, if any, of such account.

 

4.10.
Excluded Property. Except as set forth in Schedule 7, each Grantor represents, warrants and covenants that it does not,
as of the Closing Date (or the date such Grantor joins this Agreement as it relates to such Grantor), own any Excluded Property, which
by itself is, and/or when aggregated, are material to the business of such Grantor.

 

5.
Covenants.

 

Each
Grantor covenants and agrees with Agent and Lenders that, from and after the date of this Agreement until the Secured Obligations shall
have been Paid in Full:

 

5.1.
Delivery of Instruments, Certificated Securities and Chattel Paper. If any amount payable under or in connection with any of the
Collateral shall be or become evidenced by any Instrument (other than, for greater certainty, a license agreement), Certificated Security
or Chattel Paper, Grantor shall notify Agent, and upon request by Agent, such Instrument, Certificated Security or Chattel Paper shall
be promptly delivered to Agent, duly indorsed in a manner reasonably satisfactory to Agent, to be held as Collateral pursuant to this
Agreement and in the case of Electronic Chattel Paper, the applicable Grantor shall cause Agent to have control thereof within the meaning
set forth in Section 9-105 of the Code. In the event that a Default or an Event of Default shall have occurred and be continuing, upon
the request of Agent, any Instrument, Certificated Security or Chattel Paper not theretofore delivered to Agent and at such time being
held by any Grantor shall be immediately delivered to Agent, duly indorsed in a manner satisfactory to Agent, to be held as Collateral
pursuant to this Agreement and in the case of Electronic Chattel Paper, the applicable Grantor shall cause Agent to have control thereof
within the meaning set forth in Section 9-105 of the Code.

 

    	13
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

5.2.
Maintenance of Perfected Security Interest; Further Documentation.

 

(a)
Except as expressly permitted by this Agreement, the Credit Agreement, or the other Loan Documents such Grantor shall maintain the security
interest created by this Agreement as a perfected security interest having at least the priority described in Section 4.2 and
shall defend such security interest against the claims and demands of all Persons whomsoever, provided that, unless otherwise
required by Agent in writing at any time following the occurrence and continuance of an Event of Default, such security interest need
not be perfected in property of the Grantor in which a security interest may not be perfected by filing a financing statement under the
Code, having a value less than $150,000 individually or $500,000 in the aggregate.

 

(b)
Such Grantor will furnish to Agent and Lenders from time to time statements and schedules further identifying and describing the assets
and property of such Grantor and such other reports in connection therewith as Agent may reasonably request, all in reasonable detail.

 

(c)
At any time and from time to time, upon the reasonable written request of Agent, and at the sole expense of such Grantor, such Grantor
will promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as
Agent may reasonably request for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers
herein granted, including (i) filing any financing or continuation statements under the Code (or other similar laws) in effect in any
jurisdiction with respect to the security interests created hereby, (ii) in the case of Investment Property, Deposit Accounts, Electronic
Chattel Paper and Letter of Credit Rights and any other relevant Collateral, taking any actions necessary to enable Agent to obtain “control”
(within the meaning of Code) with respect thereto, in each case pursuant to documents in form and substance reasonably satisfactory to
Agent, provided that so long as no Event of Default has occurred and is continuing, no Grantor shall be required to cause the
Agent to have control over such Investment Property, Electronic Chattel Paper, Letter of Credit Rights or other relevant Collateral (other
than any Deposit Account) having a value less than $150,000 individually or $500,000 in the aggregate and (iii) upon the occurrence and
during the continuance of a Default or an Event of Default, if requested by Agent, delivering, to the extent permitted by applicable
law, any original motor vehicle certificates of title received by such Grantor from the applicable secretary of state or other Governmental
Authority after information reflecting Agent’s security interest has been recorded therein.

 

(d)
Such Grantor authorizes Agent to, at any time and from time to time, at such Grantor’s expense, file financing statements, continuation
statements, and amendments thereto that describe the Collateral (including describing the Collateral as “all assets” of each
Grantor, or words of similar effect), and which contain any other information required pursuant to the Code for the sufficiency of the
applicable filing office acceptance of any financing statement, continuation statement, or amendment, and each Grantor agrees to furnish
any such information to Agent promptly upon request. Any such financing statement, continuation statement, or amendment may be signed
(to the extent signature of a Grantor is required under applicable law) by Agent on behalf of any Grantor and may be filed at any time
in any applicable jurisdiction.

 

    	14
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(e)
Such Grantor shall, at any time and from time to time, take such steps as Agent may reasonably request (i) to obtain an acknowledgement,
in form and substance reasonably satisfactory to Agent, of any bailee having possession of any of the Collateral (provided that such
Grantor shall not be required to obtain any such acknowledgement as it relates to Collateral having a value less than $150,000 individually
or $500,000 in the aggregate unless otherwise required by Agent in writing at any time following the occurrence and continuance of an
Event of Default), stating that the bailee holds such Collateral for Agent, (ii) to obtain “control” of any Letter-of-Credit
Rights or Electronic Chattel Paper (within the meaning of the Code) constituting Collateral with any agreements establishing control
to be in form and substance reasonably satisfactory to Agent (provided that such Grantor shall not be required to ensure Agent has “control”
over any such Collateral described in this clause (ii) having a value less than $150,000 individually or $500,000 in the aggregate unless
otherwise required by Agent in writing at any time following the occurrence and continuance of a Default or an Event of Default) and
(iii) otherwise to ensure the continued perfection and priority of Agent’s security interest in any of the Collateral and of the
preservation of its rights therein to the extent required by this Agreement and the Credit Agreement.

 

(f)
Without limiting the generality of the foregoing, if any Grantor at any time holds or acquires an interest in any Electronic Chattel
Paper or any “transferable record”, as that term is defined in Section 201 of the federal Electronic Signatures in Global
and National Commerce Act, or in §16 of the Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, such
Grantor shall promptly notify Agent thereof and, at the request of Agent, shall take such action as Agent may reasonably request to vest
in Agent “control” under Section 9-105 of the Code of such electronic chattel paper or control under Section 201 of the federal
Electronic Signatures in Global and National Commerce Act or, as the case may be, §16 of the Uniform Electronic Transactions Act,
as so in effect in such jurisdiction, of such transferable record. Agent agrees with the Grantors that Agent will arrange, pursuant to
procedures reasonably satisfactory to Agent and so long as such procedures will not result in Agent’s loss of control, for the
Grantors to make alterations to such electronic chattel paper or transferable record permitted under Section 9-105 of the Code or, as
the case may be, Section 201 of the federal Electronic Signatures in Global and National Commerce Act or §16 of the Uniform Electronic
Transactions Act for a party in control to make without loss of control, unless an Event of Default has occurred and is continuing or
would occur after taking into account any action by any Grantor with respect to such electronic chattel paper or transferable record.

 

5.3.
Changes in Locations, Name, etc. Except as permitted by the Credit Agreement, each Grantor shall not, except upon 30 days’
prior written notice to Agent and delivery to Agent of (a) all additional financing statements and other documents reasonably requested
by Agent as to the validity, perfection and priority of the security interests provided for herein and (b) if applicable and requested
by Agent, a written supplement to Schedule 3 showing any additional location at which Inventory or Equipment having a fair market
value greater than $250,000 at any single location shall be kept:

 

(i)
permit any of the Inventory or Equipment to be kept at a location other than those listed on Schedule 3; provided, that
up to $250,000 in fair market value of any such Inventory and Equipment may be kept at other individual locations;

 

(ii)
change the location of its chief executive office from that specified on Schedule 2 or in any subsequent notice delivered pursuant
to this Section 5.3; or

 

(iii)
change its name, identity, corporate structure (including without limitation, the merger into or with any other Person) or its jurisdiction
of organization.

 

5.4.
[Reserved].

 

    	15
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

5.5.
Investment Property.

 

(a)
If such Grantor shall become entitled to receive or shall receive any certificate, option or rights in respect of the equity interests
of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for, any of the Pledged Equity, or otherwise
in respect thereof, such Grantor shall accept the same as the agent of Agent and Lenders, hold the same in trust for the benefit of the
Agent and Lenders, notify Agent in writing of such receipt or entitlement, and, if requested by Agent, deliver the same forthwith to
Agent in the exact form received, duly indorsed (but without any representation or warranty) by such Grantor to Agent, if required, together
with an undated instrument of transfer covering such certificate duly executed in blank by such Grantor and with, if Agent so reasonably
requests, signature guaranteed, to be held by Agent, subject to the terms hereof, as additional Collateral for the Secured Obligations.
Upon the occurrence and during the continuance of an Event of Default, (i) any sums paid upon or in respect of the Investment Property
upon the liquidation or dissolution of any Issuer shall be paid over to Agent to be held, at Agent’s option, either by it hereunder
as additional Collateral for the Secured Obligations or applied to the Secured Obligations as provided in Section 6.5, and (ii)
in case any distribution of capital shall be made on or in respect of the Investment Property or any property shall be distributed upon
or with respect to the Investment Property pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant
to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected Lien in favor of Agent, be
delivered to Agent to be held, at Agent’s option, either by it hereunder as additional Collateral for the Secured Obligations or
applied to the Secured Obligations as provided in Section 6.5. Upon the occurrence and during the continuance of an Event of Default,
if any sums of money or property so paid or distributed in respect of the Investment Property shall be received by such Grantor, such
Grantor shall, until such money or property is paid or delivered to Agent, hold such money or property in trust for Agent and Lenders,
segregated from other funds of such Grantor, as additional Collateral for the Secured Obligations.

 

(b)
Without the prior written consent of Agent, such Grantor will not, so long as an Event of Default has occurred and is continuing and
to the extent permitted by the Credit Agreement, (i) vote to enable, or take any other action to permit, any Issuer to issue any equity
interests of any nature or to issue any other securities or interests convertible into or granting the right to purchase or exchange
for any equity interests of any nature of any Issuer, (ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option
with respect to, the Investment Property or Proceeds thereof (except pursuant to a transaction expressly permitted by the Credit Agreement)
other than, with respect to Investment Property not constituting Pledged Equity or Pledged Notes, and such action which is not prohibited
by the Credit Agreement, (iii) create, incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect
to, any of the Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens, or (iv) enter into any agreement
or undertaking restricting the right or ability of such Grantor or Agent to sell, assign or transfer any of the Investment Property or
Proceeds thereof, except, with respect to such Investment Property, shareholders’ agreements entered into by such Grantor with
respect to Persons in which such Grantor maintains an ownership interest of 50% or less.

 

(c)
In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement relating
to the Investment Property issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify
Agent promptly in writing of the occurrence of any of the events described in Section 5.5(a) with respect to the Investment Property
issued by it and (iii) the terms of Section 6.3(c) shall apply to such Grantor with respect to all actions that may be required
of it pursuant to Section 6.3(c) regarding the Investment Property issued by it.

 

    	16
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

5.6.
Receivables.

 

(a)
Other than in the ordinary course of business, without the prior written consent of Agent, such Grantor will not (i) grant any extension
of the time of payment of any Receivable, (ii) compromise or settle any Receivable for less than the full amount thereof, (iii) release,
wholly or partially, any Person liable for the payment of any Receivable, (iv) allow any credit or discount whatsoever on any Receivable
or (v) amend, supplement or modify any Receivable in any manner that could materially adversely affect the value thereof, to the extent
that any action in clauses (i) - (iv) above could reasonably be expected to have a Material Adverse Effect.

 

(b)
Upon the request of Agent following the occurrence and during the continuance of an Event of Default, such Grantor will deliver to Agent
a copy of each material demand, notice or document received by it that questions or calls into doubt the validity or enforceability of
more than $250,000 of the aggregate amount of the then outstanding Receivables for all Grantors.

 

5.7.
Intellectual Property.

 

(a)
Such Grantor (either itself or through licensees) will (i) continue to use each Trademark pledged as Collateral as currently used in
order to maintain such Trademark in full force free from any claim of abandonment for non-use, (ii) maintain as in the past the quality
of products and services offered under such Trademark, (iii) use such Trademark with the appropriate notice of registration and all other
notices and legends required by applicable law, (iv) not adopt or use any mark which is confusingly similar or a colorable imitation
of such Trademark unless Agent, for the benefit of Agent and Lenders, shall obtain a perfected security interest in such mark pursuant
to this Agreement and the IP Security Agreement, and (v) not (and not permit any licensee or sublicensee thereof to) do any act or knowingly
omit to do any act whereby such Trademark may become invalidated or impaired in any way, to the extent that any action in clauses (i)
- (v) could reasonably be expected to have a Material Adverse Effect.

 

(b)
Such Grantor (either itself or through licensees) will not do any act, or omit to do any act, whereby any Patent pledged as Collateral
may become forfeited, abandoned or dedicated to the public, to the extent such act or omission could reasonably be expected to have a
Material Adverse Effect.

 

(c)
Such Grantor (either itself or through licensees) (i) will employ each Copyright pledged as Collateral and (ii) will not (and will not
permit any licensee or sublicensee thereof to) do any act or knowingly omit to do any act whereby any material portion of such Copyrights
may become invalidated or otherwise impaired and which could reasonably be expected to have a Material Adverse Effect. Such Grantor will
not (either itself or through licensees) do any act whereby any material portion of such Copyrights may fall into the public domain and
which could reasonably be expected to have a Material Adverse Effect.

 

(d)
Such Grantor (either itself or through licensees) will not do any act that knowingly uses any Intellectual Property to infringe the intellectual
property rights of any other Person.

 

(e)
Such Grantor will notify Agent and Lenders promptly if it knows, or has reason to know, that any application or registration relating
to any Intellectual Property pledged as Collateral may become forfeited, abandoned or dedicated to the public, or of any adverse determination
or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent
and Trademark Office, the United States Copyright Office, or any court or tribunal in any country) regarding, such Grantor’s ownership
of, or the validity of, any such Intellectual Property or such Grantor’s right to register the same or to own and maintain the
same, except to the extent that such forfeiture, abandonment or dedication, or adverse determination or development would not reasonably
be expected to have a Material Adverse Effect.

 

    	17
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(f)
Whenever any Grantor, either by itself or through any agent, employee, licensee or designee, shall file an application for the registration
of any Intellectual Property with the United States Patent and Trademark Office, the United States Copyright Office, or any similar office
or agency in any other country or any political subdivision thereof, such Grantor shall report such filing to Agent concurrently with
the next delivery of financial statements of Borrower and its Subsidiaries pursuant to Section 6.1.1 or 6.1.2 of the Credit
Agreement, as applicable. Upon the request of Agent, such Grantor shall execute and deliver, and have recorded, any and all agreements,
instruments, documents, and papers as Agent may reasonably request to evidence Agent’s and Lenders’ security interest in
any Copyright, Patent or Trademark and the goodwill and general intangibles of such Grantor relating thereto or represented thereby.

 

(g)
Such Grantor will take all reasonable and necessary steps to maintain and pursue each application referred to in Section 5.7(f),
(and to obtain the relevant registration), except to the extent the failure to maintain and pursue such application would not reasonably
be expected to have a Material Adverse Effect, and to maintain each registration of all Intellectual Property owned by it, except to
the extent that the failure to maintain registration of all Intellectual Property owned by it would not reasonably be expected to have
a Material Adverse Effect.

 

(h)
In the event that any Intellectual Property pledged as Collateral is infringed upon or misappropriated or diluted by a third party, such
Grantor shall (i) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Intellectual
Property and (ii) if such Intellectual Property is of material economic value, promptly notify Agent after it learns thereof and, to
the extent, in its reasonable judgment, such Grantor determines it appropriate under the circumstances, sue for infringement, misappropriation
or dilution, to seek injunctive relief where appropriate and to recover any and all damages for such infringement, misappropriation or
dilution.

 

5.8.
Deposit Accounts and Other Accounts. Each Grantor hereby authorizes the financial institutions at which such Grantor maintains
a Deposit Account, other bank account, securities account or other account to provide Agent with such information with respect to such
account as Agent may from time to time reasonably request, and each Grantor hereby consents to such information being provided to Agent.
Such Grantor will cause each financial institution at which such Grantor maintains a Deposit Account or other account to enter into a
control agreement or other similar agreement with Agent and such Grantor, in form and substance reasonably satisfactory to Agent, in
order to give Agent “control” (within the meaning set forth in Section 9-104 of the Code) of such account, except for Exempt
Accounts.

 

5.9.
Other Matters. Grantor shall cause to be delivered to Agent, at Agent’s request, a Collateral Access Agreement with respect
to (a) each bailee with which such Grantor keeps Collateral as of the Closing Date having a value in excess of $250,000 and (b) each
landlord which leases real property (and the accompanying facilities) to such Grantor as of the Closing Date at which it maintains its
chief executive office or a substantial amount of its books or records. If such Grantor shall (x) cause to be delivered Inventory or
other property constituting Collateral having a value in excess of $150,000 to any bailee after the Closing Date, such Grantor shall
on or prior to such delivery cause such bailee to sign a Collateral Access Agreement or (y) enter into any lease for real property after
the Closing Date at which it maintains its chief executive office or a substantial amount of its books and records, such Grantor shall
on or prior to the first day of the term of such lease cause the landlord to sign a Collateral Access Agreement.

 

5.10.
Commercial Tort Claims. If any Grantor shall at any time acquire any Commercial Tort Claim, such Grantor shall promptly notify
Agent thereof in writing, therein providing a reasonable description and summary thereof, and upon delivery thereof to Agent, such Grantor
shall be deemed to thereby grant to Agent (and such Grantor hereby grants to Agent), for the benefit of Agent and Lenders, a security
interest in such Commercial Tort Claim and all proceeds thereof, and such Grantor shall execute such documentation as Agent shall require
in order to document and effectuate such grant of a security interest.

 

    	18
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

6.
Remedial Provisions.

 

6.1.
Certain Matters Relating to Receivables.

 

(a)
At any time and from time to time after the occurrence and during the continuance of an Event of Default, Agent shall have the right
to make test verifications of the Receivables pledged as Collateral in any manner and through any medium that it reasonably considers
advisable, and each Grantor shall furnish all such assistance and information Agent may reasonably require in connection with such test
verifications. At any time and from time to time after the occurrence and during the continuance of an Event of Default, upon Agent’s
reasonable request and at the expense of the relevant Grantor, such Grantor shall cause independent public accountants or others reasonably
satisfactory to Agent to furnish to Agent reports showing reconciliations, agings and test verifications of, and trial balances for,
such Receivables.

 

(b)
If required by Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables
pledged as Collateral, when collected or received by or on behalf of any Grantor, (i) shall be forthwith (and, in any event, within 2
Business Days) deposited by such Grantor in the exact form received, duly indorsed (but without any representation or warranty) by such
Grantor to Agent if required, in a collateral account maintained under the sole dominion and control of Agent, for application to the
Secured Obligations in accordance with Section 6.5, and (ii) until so turned over, shall be held by such Grantor in trust for
Agent and Lenders, segregated from other funds of such Grantor. In connection with each such deposit of Proceeds of such Receivables
such Grantor shall deliver to Agent a report identifying in reasonable detail the nature and source of the payments included in the deposit.

 

(c)
At any time and from time to time after the occurrence and during the continuance of an Event of Default, at Agent’s request, each
Grantor shall deliver to Agent all original and other documents evidencing, and relating to, the agreements and transactions which gave
rise to such Receivables, including all original orders, invoices and shipping receipts.

 

6.2.
Communications with Obligors; Grantors Remain Liable.

 

(a)
Agent in its own name or in the name of others may at any time after the occurrence and during the continuance of an Event of Default
communicate with obligors under the Receivables pledged as Collateral to verify with them to Agent’s reasonable satisfaction the
existence, amount and terms of such Receivables.

 

(b)
Upon the request of Agent at any time after the occurrence and during the continuance of an Event of Default, each Grantor shall notify
obligors on such Receivables that such Receivables have been assigned to Agent for the benefit of Agent and Lenders and that payments
in respect thereof shall be made directly to Agent.

 

(c)
Anything herein to the contrary notwithstanding, each Grantor shall remain liable in respect of each of the Receivables to observe and
perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement
giving rise thereto. Neither Agent nor any Lender shall have any obligation or liability under any Receivable (or any agreement giving
rise thereto) by reason of or arising out of this Agreement or the receipt by Agent or any Lender of any payment relating thereto, nor
shall Agent or any Lender be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any Receivable
(or any agreement giving rise thereto), to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received
by it or as to the sufficiency of any performance by any party thereunder, to present or file any claim, to take any action to enforce
any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time
or times.

 

    	19
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(d)
For the purpose of enabling Agent to exercise rights and remedies under this Agreement, each Grantor hereby grants to Agent, for the
benefit of Agent and Lenders, an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such
Grantor) to use, license or sublicense any Intellectual Property that constitutes part of the Collateral now owned or hereafter acquired
by such Grantor, to the extent such Intellectual Property may be so licensed or sublicensed, and wherever the same may be located, and
including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software
and programs used for the compilation or printout thereof.

 

6.3.
Investment Property.

 

(a)
Unless an Event of Default shall have occurred and be continuing and Agent shall have given notice to the relevant Grantor of Agent’s
intent to exercise its corresponding rights pursuant to Section 6.3(b), each Grantor shall be permitted to receive all cash dividends
and distributions, payments and Proceeds paid in respect of the Pledged Equity, the Pledged Notes and all other Investment Property that
constitutes Collateral, to the extent permitted in the Credit Agreement, and to exercise all voting and other rights and any and all
rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Pledged Equity, Pledged
Notes and Investment Property (including the right to exchange at its discretion any and all of the Investment Property upon the merger,
consolidation, reorganization, recapitalization or other fundamental change in the corporate or other structure of any Issuer, or upon
the exercise by such Grantor of any right, privilege or option pertaining to such Pledged Equity, Pledged Notes or Investment Property,
and in connection therewith, the right to deposit and deliver any and all of such Pledged Equity, Pledged Notes and Investment Property
with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as such Grantor may
determine); provided, that no vote shall be cast or other right exercised or action taken which would be inconsistent with or
result in any violation of any provision of the Credit Agreement, this Agreement or any other Loan Document.

 

(b)
If an Event of Default shall occur and be continuing, upon five (5) Business Days’ advance notice to the relevant Grantor, Agent
shall have the right to (i) receive any and all cash dividends and distributions, payments or other Proceeds paid in respect of the Pledged
Equity, the Pledged Notes and all other Investment Property pledged as Collateral and make application thereof to the Secured Obligations
in accordance with Section 6.5, (ii) register any or all of such Investment Property in the name of Agent or its nominee, (iii)
exercise, or permit its nominee to exercise, all voting and other rights pertaining to such Investment Property, and (iv) exercise, or
permit its nominee to exercise, any and all rights of conversion, exchange and subscription and any other rights, privileges or options
pertaining to such Investment Property as if it were the absolute owner thereof (including the right to exchange at its discretion any
and all of the Investment Property upon the merger, consolidation, reorganization, recapitalization or other fundamental change in the
corporate or other structure of any Issuer, or upon the exercise by any Grantor or Agent of any right, privilege or option pertaining
to such Investment Property, and in connection therewith, the right to deposit and deliver any and all of such Investment Property with
any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as Agent may determine),
all without liability except to account for property actually received by it, but Agent shall have no duty to exercise any such right,
privilege or option and shall not be responsible for any failure to do so or delay in so doing.

 

    	20
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(c)
Each Grantor hereby authorizes and instructs each Issuer of any Investment Property pledged by such Grantor hereunder to (i) comply with
any instruction received by it from Agent in writing that (x) states that an Event of Default has occurred and is continuing and (y)
is otherwise in accordance with the terms of this Agreement and the Credit Agreement, without any other or further instructions from
such Grantor, and each Grantor agrees that each Issuer shall be fully protected in so complying, and (ii) unless otherwise expressly
permitted hereby, pay any dividends, distributions or other payments with respect to the Investment Property directly to Agent.

 

6.4.
Proceeds to be Turned Over To Agent. In addition to the rights of Agent specified in Section 6.1 with respect to payments
of Receivables pledged as Collateral, if an Event of Default shall occur and be continuing, all such Proceeds of Collateral received
by or on behalf of any Grantor consisting of cash, checks and other cash equivalent items shall be held by such Grantor in trust for
Agent and Lenders, segregated from other funds of such Grantor, and shall, at the written request of Agent, forthwith upon receipt by
such Grantor, be turned over to Agent in the exact form received by such Grantor (duly indorsed (but without any representation or warranty)
by such Grantor to Agent, if required). All Proceeds received by Agent hereunder shall be applied to the Secured Obligations as provided
in Section 6.5.

 

6.5.
Application of Proceeds. If an Event of Default shall have occurred and be continuing, Agent shall apply all or any part of Proceeds
held in any collateral account established pursuant hereto or otherwise received by Agent to the payment of the Secured Obligations in
a manner that is consistent with the provisions of Section 2.10.2 of the Credit Agreement.

 

6.6.
Code and Other Remedies. If an Event of Default shall occur and be continuing, Agent, on behalf of Agent and Lenders, may exercise,
in addition to all other rights and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing
or relating to the Secured Obligations, all rights and remedies of a secured party under the Code, or any other applicable foreign or
domestic law. Without limiting the generality of the foregoing, if an Event of Default shall occur or be continuing, Agent, without demand
of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred
to below) to or upon any Grantor or any other Person (all and each of which demands, defenses, advertisements and notices are hereby
waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and/or
may forthwith sell, lease, assign, give options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or
contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board
or office of Agent or any Lender or elsewhere upon such terms and conditions as it may deem advisable and at such prices as it may deem
best, for cash or on credit or for future delivery with assumption of any credit risk. Agent may disclaim any warranties that might arise
in connection with any such lease, assignment, grant of option or other disposition of Collateral and have no obligation to provide any
warranties at such time. Agent or any Lender shall have the right upon any such public sale or sales, and, to the extent permitted by
law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of
redemption in any Grantor, which right or equity is hereby waived and released. Such sales may be adjourned and continued from time to
time with or without notice. Agent shall have the right to conduct such sales on any Grantor’s premises or elsewhere and shall
have the right to use any Grantor’s premises without charge for such time or times as Agent deems necessary or advisable. Each
Grantor further agrees after an Event of Default has occurred and is continuing, at Agent’s request, to assemble the Collateral
and make it available to Agent at places which Agent shall reasonably select, whether at such Grantor’s premises or elsewhere.
Agent shall apply the net proceeds of any action taken by it pursuant to this Section 6.6, after deducting all reasonable costs
and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any
way relating to the Collateral or the rights of Agent and Lenders hereunder, including reasonable attorneys’ fees and disbursements,
to the payment of the Secured Obligations in a manner that is consistent with the provisions of Section 2.10.2 of the Credit Agreement.
To the extent permitted by applicable law, each Grantor waives all claims, damages and demands it may acquire against Agent or any Lender
arising out of the exercise by them of any rights hereunder, except to the extent such claims, damages or demands arise from the gross
negligence or willful misconduct of the Agent or Lenders as determined by a court of competent jurisdiction in a non-appealable order.
If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable
and proper so long as (a) it is given at least 15 days before such sale or other disposition, and (b) contains such information as may
be prescribed by applicable law.

 

    	21
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

6.7.
Pledged Equity. Each Grantor recognizes that Agent may be unable to effect a public sale of any or all the Pledged Equity, by
reason of certain prohibitions contained in the Securities Act and other applicable securities laws or otherwise, and may be compelled
to resort to one or more private sales thereof to a restricted group of purchasers which will be obliged to agree, among other things,
to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof. Each Grantor
acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public
sale and, notwithstanding such circumstances, agrees that any such private sale shall be deemed to have been made in a commercially reasonable
manner. Agent shall be under no obligation to delay a sale of any of the Pledged Equity for the period of time necessary to permit the
Issuer thereof to register such securities or other interests for public sale under the Securities Act, or other applicable state securities
laws, even if such Issuer would agree to do so.

 

6.8.
Deficiency. Each Grantor shall remain liable for any deficiency if the proceeds of any sale or other disposition of the Collateral
are insufficient for the Secured Obligations to be Paid in Full and the fees and disbursements of any attorneys employed by Agent or
any Lender to collect such deficiency.

 

6.9.
Permitted Licenses. Agent hereby covenants and agrees that in connection with any foreclosure or other exercise of Agent’s
rights with respect to Permitted Licenses, Agent shall not terminate, limit, or otherwise adversely affect the rights of the licensees
or sublicensees under such Permitted Licenses, so long as such licensee or sublicensee is not then otherwise in default under the applicable
Permitted License in a way that would permit the applicable licensor to terminate such Permitted License.

 

6.10.
Actions in Concert. Section 9.12 of the Credit Agreement shall be incorporated herein by reference.

 

7.
Agent.

 

7.1.
Agent’s Appointment as Attorney-in-Fact, etc.

 

(a)
Each Grantor hereby irrevocably constitutes and appoints Agent and any officer or agent thereof, with full power of substitution, as
its true and lawful attorney-in-fact and proxy with full irrevocable power and authority in the place and stead of such Grantor and in
the name of such Grantor or in its own name, for the purpose of strictly carrying out the terms of this Agreement, to take any and all
appropriate action and to execute any and all documents and instruments which may be necessary or desirable to accomplish the purposes
of this Agreement, in each case, at any time following the occurrence and during the continuance of an Event of Default, and, without
limiting the generality of the foregoing, each Grantor hereby gives Agent the power and right, on behalf of and at the expense of such
Grantor, without notice to or assent by such Grantor, to do any or all of the following to the extent otherwise expressly permitted by
the terms of this Agreement and the Credit Agreement (including the satisfaction of any requirement to give notice to such Grantor prior
to doing any of the following), in each case, at any time following the occurrence and during the continuance of an Event of Default:

 

    	22
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(i)
in the name of such Grantor or its own name, or otherwise, take possession of and indorse (but without any representation or warranty)
and collect any checks, drafts, notes, acceptances or other instruments for the payment of moneys due under any Receivable or with respect
to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise reasonably
deemed appropriate by Agent for the purpose of collecting any and all such moneys due under any Receivable pledged as Collateral or with
respect to any other Collateral whenever payable;

 

(ii)
in the case of any Intellectual Property pledged as Collateral, execute and deliver, and have recorded, any and all agreements, instruments,
documents and papers as Agent may reasonably request to evidence Agent’s security interest in such Intellectual Property and the
goodwill and general intangibles of such Grantor relating thereto or represented thereby;

 

(iii)
discharge Liens (other than Permitted Liens) levied or placed on or threatened against the Collateral, and effect any repairs or insurance
called for by the terms of this Agreement and pay all or any part of the premiums therefor and the costs thereof;

 

(iv)
execute, in connection with any sale provided for in Section 6.6 or 6.7, any indorsements, assignments or other instruments
of conveyance or transfer with respect to the Collateral, in each case upon not less than thirty (30) days’ prior written notice
to Borrower; and

 

(v)
(A) direct any party liable for any payment under any of the Collateral to make payment of any and all moneys due or to become due thereunder
directly to Agent or as Agent shall direct; (B) ask or demand for, collect, and receive payment of and receipt for, any and all moneys,
claims and other amounts due or to become due at any time in respect of or arising out of any Collateral; (C) sign and indorse (but without
any representation or warranty) any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against
debtors, assignments, verifications, notices and other documents in connection with any of the Collateral; (D) commence and prosecute
any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any portion
thereof and to enforce any other right in respect of any Collateral; (E) defend any suit, action or proceeding brought against such Grantor
with respect to any Collateral; (F) settle, compromise or adjust any such suit, action or proceeding and, in connection therewith, give
such discharges or releases as Agent may deem appropriate; (G) assign any Copyright, Patent or Trademark pledged as Collateral, throughout
the world for such term or terms, on such conditions, and in such manner, as Agent shall in its sole discretion determine, in each case
upon not less than thirty (30) days’ prior written notice to Borrower; (H) vote any right or interest with respect to any Investment
Property pledged as Collateral; (I) order good standing certificates and conduct lien searches in respect of such jurisdictions or offices
as Agent may deem appropriate; and (J) generally sell, transfer, pledge and make any agreement with respect to or otherwise deal with
any of the Collateral as fully and completely as though Agent were the absolute owner thereof for all purposes, and do, at Agent’s
option and such Grantor’s expense, at any time, or from time to time, all acts and things which Agent deems necessary to protect,
preserve or realize upon the Collateral and Agent’s security interests therein and to effect the intent of this Agreement, all
as fully and effectively as such Grantor might do, in each case upon not less than thirty (30) days’ prior written notice to Borrower.

 

    	23
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

(b)
THE POWER-OF-ATTORNEY AND PROXY GRANTED HEREBY IS COUPLED WITH AN INTEREST AND SHALL BE IRREVOCABLE TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW. SUCH PROXY SHALL BE EFFECTIVE AUTOMATICALLY AND WITHOUT THE NECESSITY OF ANY ACTION (INCLUDING ANY TRANSFER OF ANY INVESTMENT
PROPERTY ON THE RECORD BOOKS OF THE ISSUER THEREOF) BY ANY PERSON (INCLUDING THE ISSUER OF THE INVESTMENT PROPERTY OR ANY OFFICER OR
AGENT THEREOF). Each Grantor acknowledges and agrees that in any event such power-of-attorney and proxy is intended to and shall, to
the fullest extent permitted by applicable law, be valid and irrevocable until (x) the Secured Obligations have been Paid in Full and
(y) Lenders and Agent have no further obligations under the Loan Documents (excluding any obligations under the Residual Royalty Agreement).
Such power-of-attorney and proxy shall be valid and irrevocable as provided herein notwithstanding any limitations to the contrary set
forth in the charter, bylaws or other organizational documents of the relevant entities.

 

(c)
Upon exercise of the proxy set forth herein, all prior proxies given by any Grantor with respect to any of the Investment Property pledged
as Collateral (other than to Agent or otherwise pursuant to the Loan Documents) are hereby revoked, and until the Secured Obligations
are Paid in Full no subsequent proxies (other than to Agent or otherwise under the Loan Documents) will be given with respect to any
of such Investment Property. To the extent permitted by this Agreement, Agent, as proxy, will be empowered and may exercise the irrevocable
proxy to vote such Investment Property at any and all times, including but not limited to, at any meeting of shareholders, partners or
members, as the case may be, however called, and at any adjournment thereof, or in any action by written consent, and may waive any notice
otherwise required in connection therewith. To the fullest extent permitted by applicable law, Agent shall have no agency, fiduciary
or other implied duties to any Grantor or any other party when acting in its capacity as such attorney-in-fact or proxy. Each Grantor
hereby waives and releases any claims that it may otherwise have against Agent with respect to any breach or alleged breach of any such
agency, fiduciary or other duty, other than claims resulting from the gross negligence or willful misconduct of Agent as determined by
a court of competent jurisdiction in a non-appealable order. Notwithstanding the foregoing grant of a power of attorney and proxy, Agent
shall have no duty to exercise any such right or to preserve the same and shall not be liable for any failure to do so or for any delay
in doing so.

 

(d)
Anything in Section 7.1(a) to the contrary notwithstanding, Agent agrees that it will not exercise any rights under the power
of attorney provided for in this Section 7.1 unless an Event of Default shall have occurred and be continuing.

 

(e)
If any Grantor fails to perform or comply with any of its agreements contained herein, Agent, at its option, but without any obligation
so to do, may perform or comply, or otherwise cause performance or compliance, with such agreement at such Grantor’s sole cost
and expense.

 

(f)
Each Grantor hereby ratifies that such attorneys shall be authorized hereunder to lawfully do or cause to be done by virtue hereof. All
powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement
is terminated and the security interests created hereby are released.

 

7.2.
Duty of Agent. Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in
its possession shall be to deal with it in the same manner as Agent deals with similar property for its own account. Neither Agent or
any Lender nor any of their respective officers, directors, employees or agents shall be liable for any failure to demand, collect or
realize upon any of the Collateral or for any delay in doing so (except to the extent Agent, such Lender or such officers, directors,
employees or agents acted with gross negligence or in willful misconduct as determined by a court of competent jurisdiction in a non-appealable
order) or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person
or to take any other action whatsoever with regard to the Collateral or any part thereof. The powers conferred on Agent and Lenders hereunder
are solely to protect Agent’s and Lenders’ interests in the Collateral and shall not impose any duty upon Agent or any Lender
to exercise any such powers. Agent and Lenders shall be accountable only for amounts that they actually receive as a result of the exercise
of such powers, and neither they nor any of their officers, directors, employees or agents shall be responsible to any Grantor for any
act or failure to act hereunder, except to the extent Agent or a Lender (or such officer, director, employee or agent) acted with gross
negligence or in willful misconduct as determined by a court of competent jurisdiction in a non-appealable order.

 

    	24
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

7.3.
Photocopy of this Agreement. A photographic or other reproduction of this Agreement shall be sufficient as a financing statement
or other filing or recording document or instrument for filing or recording in any jurisdiction.

 

7.4.
Authority of Agent. Each Grantor acknowledges that the rights and responsibilities of Agent under this Agreement with respect
to any action taken by Agent or the exercise or non-exercise by Agent of any option, voting right, request, judgment or other right or
remedy provided for herein or resulting or arising out of this Agreement shall, as between Agent and Lenders, be governed by the Credit
Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between Agent and the
Grantors, Agent shall be conclusively presumed to be acting as agent for Lenders with full and valid authority to act or refrain from
acting, and no Grantor shall be under any obligation, or entitlement, to make any inquiry respecting such authority.

 

8.
Miscellaneous.

 

8.1.
Further Assurances. In the event that Agent and Grantor agree, in their mutual and reasonable discretion, that being a party to
this Agreement, granting of Liens hereunder and the related transactions contemplated herein in relation to any Subsidiary that is organized
outside of the United States (a “Inactive Foreign Subsidiary”) may cause such Inactive Foreign Subsidiary to suffer
a material, negative tax consequence (or any other under burden in light of the operations and/or assets of such Inactive Foreign Subsidiary)
to the Grantor and/or one of its Subsidiaries, then Agent and Grantor shall work together in good faith, as may be necessary to limit
the obligations hereunder and under any other Loan Documents. Agent (on behalf of itself and Lenders) hereby acknowledges and agrees
that, as of the Closing Date, iMedical Innovation Inc. shall constitute an Inactive Foreign Subsidiary and shall not be required to join
this Agreement for so long as its assets and business operations are not otherwise material, as determined by Agent in its commercially-reasonable
discretion, to the overall business of Loan Parties.

 

8.2.
Amendments in Writing. None of the terms or provisions of this Agreement may be waived, amended, supplemented or otherwise modified
except in accordance with Section 10.1 of the Credit Agreement.

 

8.3.
Notices. All notices, requests and demands to or upon Agent or any Grantor hereunder shall be effected in the manner provided
for in Section 10.2 of the Credit Agreement and each such notice, request or demand to or upon any Grantor shall be addressed
to such Grantor in care of Borrower at Borrower’s notice address set forth on Schedule 1.

 

    	25
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

8.4.
Indemnification by Grantors. Each Grantor hereby agrees, on a joint and several basis, to indemnify, exonerate and hold Agent,
each Lender and each of the officers, directors, employees, Affiliates and agents of Agent and each Lender (each a “Lender Party”
and collectively, the “Lender Parties”) free and harmless from and against any and all actions, causes of action,
suits, losses, liabilities, damages and expenses, including Legal Costs, but expressly excluding any consequential, special or lost profits
damages (collectively, the “Indemnified Liabilities”), incurred by Lender Parties or any of them as a result of, or
arising out of, or relating to any act or omission by Borrower or any of its officer, directors, agents, including without limitation
(a) any tender offer, merger, purchase of equity interests, purchase of assets or other similar transaction financed or proposed to be
financed in whole or in part, directly or indirectly, with the proceeds of any of the Loans, (b) the use, handling, release, emission,
discharge, transportation, storage, treatment or disposal of any hazardous substance at any property owned or leased by any Grantor or
any Subsidiary, (c) any violation of any Environmental Laws with respect to conditions at any property owned or leased by any Grantor
or any Subsidiary or the operations conducted thereon, (d) the investigation, cleanup or remediation of offsite locations at which any
Grantor or any Subsidiary or their respective predecessors are alleged to have directly or indirectly disposed of hazardous substances,
or (e) the execution, delivery, performance or enforcement of this Agreement or any other Loan Document by any Lender Party, except,
in each case, to the extent any such Indemnified Liabilities result from the applicable Lender Party’s own gross negligence or
willful misconduct as determined by a court of competent jurisdiction in a non-appealable order. If and to the extent that the foregoing
undertaking may be unenforceable for any reason, each Grantor hereby agrees to make the maximum contribution to the payment and satisfaction
of each of the Indemnified Liabilities which is permissible under applicable law. The agreements in this Section 8.4 shall survive
repayment of the Secured Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral
Documents and termination of this Agreement.

 

8.5.
Enforcement Expenses.

 

(a)
Each Grantor agrees, on a joint and several basis, to pay or reimburse on demand each Lender and Agent for all reasonable out-of-pocket
costs and expenses (including Legal Costs) incurred in collecting against any Guarantor under the guarantee contained in Section 2
or otherwise enforcing or preserving any rights under this Agreement and the other Loan Documents.

 

(b)
Each Grantor agrees to pay, and to save Agent and Lenders harmless from, any and all liabilities with respect to, or resulting from any
delay in paying, any and all stamp, excise, sales or other taxes which may be payable or determined to be payable with respect to any
of the Collateral or in connection with any of the transactions contemplated by this Agreement.

 

(c)
The agreements in this Section 8.5 shall survive repayment of the Secured Obligations, any foreclosure under, or any modification,
release or discharge of, any or all of the Collateral Documents and termination of this Agreement.

 

8.6.
Captions. Captions used in this Agreement are for convenience only and shall not affect the construction of this Agreement.

 

8.7.
Nature of Remedies. All Secured Obligations of each Grantor and rights of Agent and Lenders expressed herein or in any other Loan
Document shall be in addition to and not in limitation of those provided by applicable law. No failure to exercise and no delay in exercising,
on the part of Agent or any Lender, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any
single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise
of any other right, remedy, power or privilege.

 

8.8.
Counterparts; Electronic Signatures. This Agreement may be executed in counterparts with the same effect as if all parties had
executed the same document. All counterparts shall be construed together and shall constitute a single agreement. Further, the parties
hereto consent and agree that this Agreement may be signed and/or transmitted by e-mail of any .pdf file, .jpeg file, or any other electronic
or image file, or any “electronic signature” as defined under the U.S. Electronic Signatures in Global and National Commerce
Act or the New York Electronic Signatures and Records Act, which includes any electronic signature provided using Orbit, Adobe Sign,
DocuSign, or any other similar platform identified by the parties hereto and reasonably available at no undue burden or expense to the
Agent), except to the extent the Agent requires otherwise. Any such electronic signatures shall be valid, effective and legally binding
as if such electronic signatures were handwritten signatures and shall be deemed to have been duly and validly delivered for all purposes
hereunder. No party hereto shall raise the use of e-mail or other electronic transmission to deliver a signature or the fact that any
signature or agreement or amendment was transmitted or communicated through the use of e-mail or other electronic transmission as a defense
to the formation or enforceability of a contract and each such party forever waives any such defense.

 

    	26
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

8.9.
Severability. The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder
shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument
or agreement required hereunder.

 

8.10.
Entire Agreement. This Agreement, together with the other Loan Documents, embodies the entire agreement and understanding among
the parties hereto and supersedes all prior or contemporaneous agreements and understandings of such Persons, verbal or written, relating
to the subject matter hereof and thereof and any prior arrangements made with respect to the payment by any Grantor of (or any indemnification
for) any fees, costs or expenses payable to or incurred (or to be incurred) by or on behalf of Agent or Lenders.

 

8.11.
Successors; Assigns. This Agreement shall be binding upon Grantors, Lenders and Agent and their respective successors and assigns,
and shall inure to the benefit of Grantors, Lenders and Agent and the successors and assigns of Lenders and Agent. No other Person shall
be a direct or indirect legal beneficiary of, or have any direct or indirect cause of action or claim in connection with, this Agreement
or any of the other Loan Documents. No Grantor may assign or transfer any of its rights or Obligations under this Agreement without the
prior written consent of Agent.

 

8.12.
Governing Law. THIS AGREEMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE
TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE.

 

8.13.
Forum Selection; Consent to Jurisdiction. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT
OR ANY OTHER LOAN DOCUMENT, SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF NEW YORK OR IN THE UNITED STATES
DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER
PROPERTY MAY BE BROUGHT, AT AGENT’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND.
EACH PARTY HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK AND OF THE UNITED STATES
DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK FOR THE PURPOSE OF ANY SUCH LITIGATION AS SET FORTH ABOVE. EACH PARTY FURTHER IRREVOCABLY
CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, U.S. FIRST CLASS POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE
STATE OF NEW YORK. EACH PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED UNDER APPLICABLE LAW, ANY OBJECTION
WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY
CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

 

    	27
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

8.14.
Waiver of Jury Trial. EACH GRANTOR, AGENT AND EACH LENDER, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY WAIVES ANY
RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT AND ANY AMENDMENT, INSTRUMENT,
DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH AND AGREES THAT ANY SUCH ACTION OR PROCEEDING
SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

 

8.15.
Set-off. Each Grantor agrees that Agent and each Lender have all rights of set-off and bankers’ lien provided by applicable
law, and in addition thereto, each Grantor agrees that at any time any Event of Default has occurred and is continuing, Agent and each
Lender may apply to the payment of any Secured Obligations, whether or not then due, any and all balances, credits, deposits, accounts
or moneys of such Grantor then or thereafter with Agent or such Lender.

 

8.16.
Acknowledgements. Each Grantor hereby acknowledges that:

 

(a)
it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it
is a party;

 

(b)
it has received a fully executed copy of this Agreement;

 

(c)
neither Agent nor any Lender has any fiduciary relationship with or duty to any Grantor arising out of or in connection with this Agreement
or any of the other Loan Documents, and the relationship between the Grantors, on the one hand, and Agent and Lenders, on the other hand,
in connection herewith or therewith is solely that of debtor and creditor; and

 

(d)
no joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby
among Lenders or among the Grantors and Lenders.

 

8.17.
Additional Grantors. Each Loan Party that is required to become a party to this Agreement pursuant to Sections 6.8 and
7.14 of the Credit Agreement shall become a Grantor for all purposes of this Agreement upon execution and delivery by such Loan
Party of a joinder agreement in the form of Annex I hereto.

 

8.18.
Releases.

 

(a)
At such time as the Secured Obligations have been Paid in Full, the Collateral shall be released from the Liens created hereby, and this
Agreement and all obligations (other than those expressly stated to survive such termination) of Agent and each Grantor hereunder shall
terminate, all without delivery of any instrument or performance of any act by any party, and all rights in and to the Collateral shall
revert to the Grantors. At the request and sole expense of any Grantor following any such termination, Agent shall deliver to the Grantors
any Collateral held by Agent hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request
to evidence such termination.

 

(b)
If any of the Collateral shall be sold or otherwise disposed of by any Grantor in a transaction permitted by the Credit Agreement, then
Agent, at the request and sole expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents reasonably
necessary or desirable for the release of the Liens created hereby on such Collateral, so long as Borrower delivers to Agent a certificate
of an officer of Borrower as to such sale or disposition being made in compliance with the Loan Documents. At the request and sole expense
of Borrower, a Guarantor shall be released from its obligations hereunder in the event that all the equity interests of such Guarantor
shall be sold, transferred, liquidated, dissolved or otherwise disposed of in a transaction permitted by the Credit Agreement; provided
that Borrower shall have delivered to Agent, with reasonable notice prior to the date of the proposed release, a written request
for release identifying the relevant Guarantor and the terms of the sale or other disposition in reasonable detail, including the price
thereof and any expenses in connection therewith, together with a certification by Borrower stating that such transaction is in compliance
with the Credit Agreement and the other Loan Documents.

 

    	28
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

8.19.
Obligations and Liens Absolute and Unconditional. Each Grantor understands and agrees that the obligations of each Grantor under
this Agreement shall be construed as continuing, absolute and unconditional without regard to (a) the validity or enforceability of any
Loan Document, any of the Secured Obligations or any other collateral security therefor or guarantee or right of offset with respect
thereto at any time or from time to time held by Agent or any Lender, (b) any defense, set-off or counterclaim (other than a defense
of payment or performance) which may at any time be available to or be asserted by any Grantor or any other Person against Agent or any
Lender, or (c) any other circumstance whatsoever (with or without notice to or knowledge of any Grantor) which constitutes, or might
be construed to constitute, an equitable or legal discharge of any Grantor for the Secured Obligations, in bankruptcy or in any other
instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor, Agent or any
Lender may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as it may have
against any other Grantor or any other Person or against any collateral security or guarantee for the Secured Obligations or any right
of offset with respect thereto, and any failure by Agent or any Lender to make any such demand, to pursue such other rights or remedies
or to collect any payments from any other Grantor or any other Person or to realize upon any such collateral security or guarantee or
to exercise any such right of offset, or any release of any other Grantor or any other Person or any such collateral security, guarantee
or right of offset, shall not relieve any Grantor of any obligation or liability hereunder, and shall not impair or affect the rights
and remedies, whether express, implied or available as a matter of law, of Agent or any Lender against any Grantor. For the purposes
hereof “demand” shall include the commencement and continuance of any legal proceedings.

 

8.20.
Reinstatement. This Agreement shall remain in full force and effect and continue to be effective should any petition be filed
by or against any Grantor or any Issuer for liquidation or reorganization, should any Grantor or any Issuer become insolvent or make
an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any significant part of any Grantor’s
or any Issuer’s assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance
of the Secured Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be
restored or returned by any obligee of the Secured Obligations, whether as a “voidable preference”, “fraudulent conveyance”,
or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded,
reduced, restored or returned, the Secured Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded,
reduced, restored or returned.

 

8.21.
Conflicting Terms. In the event of any conflict or inconsistency between the terms of this Agreement and the terms of the Credit
Agreement, the terms of the Credit Agreement shall control.

 

[Remainder
of page intentionally left blank; signature pages follow.]

 

    	29
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

Each
of the undersigned has caused this Guarantee and Collateral Agreement to be duly executed and delivered as of the date first above written.

 

	 	GRANTORS:
	 	 	 
	 	biotricity
    INC.,
	 	a
    Nevada corporation
	 	 	            
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

	 	AGENT:
	 	 	 
	 	SWK
    FUNDING LLC,
	 	as
    Agent
	 	 	 
	 	By:
    	SWK
    Holdings Corporation,
	 	 	its
    sole Manager
	 	 	 
	 	By:	 
	 	Name:	Winston
    Black
	 	Title:	Chief
    Executive Officer

 

    	
	[Biotricity] Guarantee and Collateral Agreement

     

    

 

SCHEDULE
1

 

INVESTMENT
PROPERTY

 

	A.	PLEDGED EQUITY
	 	N/A
	 	 
	B.	PLEDGED NOTES
	 	N/A
	 	 
	C.	OTHER INVESTMENT PROPERTY
	 	N/A
	 	 
	D.	NOTICE ADDRESS
	 	N/A

 

    	[Schedule 1]
Guarantee and Collateral Agreement

     

    

 

SCHEDULE
2

 

GRANTOR
INFORMATION

 

	Grantor

                                                                                (exact
                                            legal name)
	 	Jurisdiction
    of Organization	 	Federal
    Employer Identification Number	 	Chief
    Executive Office	 	Organizational
    Identification Number
	Biotricity
    Inc.	 	State
    of Nevada	 	30-0983531	 	203
    Redwood Shores Pkwy, Suite 600 Redwood City CA 94065	 	CIK
    0001630113

 

    	[Schedule 2]
Guarantee and Collateral Agreement

     

    

 

SCHEDULE
3

 

	A.	COLLATERAL LOCATIONS

 

	Grantor	 	Collateral
                                            Location or

    Place
    of Business

    (including
    chief executive office)
	 	Owner/Lessor

    

    (if
    leased)

	Biotricity
    Inc.	 	203
    Redwood Shores Pkwy, Suite 600 Redwood City CA 94065	 	Hudson
    Properties

 

 

	B.	COLLATERAL IN POSSESSION OF LESSOR,
	 	BAILEE, CONSIGNEE OR WAREHOUSEMAN

 

	Grantor	 	Collateral	 	Lessor/Bailee/Consignee/Warehouseman
	N/A	 	 	 	 

 

    	[Schedule 3]
Guarantee and Collateral Agreement

     

    

 

SCHEDULE
4

 

INTELLECTUAL
PROPERTY

 

Patents

 

	Ref.
    No.	 	Description/Application
    No.	 	Status	 	Title
	US
    D812,229 S	 	Design
    Patent 29/550,849	 	Live	 	ECG
    Monitoring Device

 

    	[Schedule 4]
Guarantee and Collateral Agreement

     

    

 

Copyrights

 

None.

 

    	[Schedule 4]
Guarantee and Collateral Agreement

     

    

 

Trademarks

 

	Description	 	Serial
    Number	 	Registration
    Number 
	BIOFLUX	 	87809393	 	5700945

 

    	[Schedule 4]
Guarantee and Collateral Agreement

     

    

 

Mask
Works

 

None.

 

    	[Schedule 4]
Guarantee and Collateral Agreement

     

    

 

SCHEDULE
5

 

DEPOSIT
ACCOUNTS AND OTHER ACCOUNTS

 

	Bank
    Name	 	Account
    Holder	 	Account
    Number	 	Branch
    Address
	Bank
    of America	 	Biotricity
    Inc.	 	325053293293	 	P.O
    Box 15284 Wilmington DE 19850

 

    	[Schedule 5]
Guarantee and Collateral Agreement

     

    

 

SCHEDULE
6

 

COMMERCIAL
TORT CLAIMS

 

None

 

    	[Schedule 6]
Guarantee and Collateral Agreement

     

    

 

SCHEDULE
7

 

EXCLUDED
PROPERTY

 

	Description	 	Serial
    Number	 	Registration
    Number 
	BIOHEART	 	97080037	 	 
	BIONATAL	 	90009577	 	 
	MCT
    PEEK	 	88491674	 	 
	SYNCLYNC	 	88491719	 	 
	BIOTRICITY	 	88938414	 	 

 

    	[Schedule 7]
Guarantee and Collateral Agreement

     

    

 

SCHEDULE
8

 

SPECIAL
COLLATERAL

 

None.

 

    	[Schedule 8]
Guarantee and Collateral Agreement

     

    

 

ANNEX
I

FORM
OF JOINDER TO GUARANTEE AND COLLATERAL AGREEMENT

 

This
JOINDER AGREEMENT (this “Agreement”) dated as of [__], 20[__] is executed by the undersigned for the benefit of SWK
Funding LLC, as Agent (the “Agent”) in connection with that certain Guarantee and Collateral Agreement dated as of
December [__], 2021, among the Grantors party thereto and Agent (as amended, supplemented or modified from time to time, the “Guarantee
and Collateral Agreement”). Capitalized terms not otherwise defined herein are being used herein as defined in the Guarantee
and Collateral Agreement.

 

Each
Person signatory hereto is required to execute this Agreement pursuant to Section 8.16 of the Guarantee and Collateral Agreement.

 

NOW
THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, each signatory hereby agrees as follows:

 

1.
Each such Person assumes all the obligations of a Grantor and a Guarantor under the Guarantee and Collateral Agreement and agrees that
such Person is a Grantor and a Guarantor and bound as a Grantor and a Guarantor under the terms of the Guarantee and Collateral Agreement,
as if it had been an original signatory to the Guarantee and Collateral Agreement. In furtherance of the foregoing, such Person hereby
(i) assigns, pledges and grants to Agent, for the benefit of Agent and Lenders, a security interest in all of its right, title and interest
in and to the Collateral owned thereby to secure the Secured Obligations and (ii) guarantees the prompt and complete payment and performance
by Borrower when due (whether at the stated maturity, by acceleration or otherwise) of Borrower Obligations.

 

2.
Schedules 1, 2, 3, 4, 5, 6, 7, and 8 of the Guarantee and Collateral Agreement
are hereby amended and restated in the forms of Schedules 1, 2, 3, 4, 5, 6, 7, and 8,
respectively, hereof. Each such Person and all existing Grantors hereby make to Agent the representations and warranties set forth in
the Guarantee and Collateral Agreement applicable to such Person and the applicable Collateral and confirms that such representations
and warranties are true and correct after giving effect to such amendment to such Schedules.

 

3.
In furtherance of its obligations under Section 5.2 of the Guarantee and Collateral Agreement, each such Person authorizes Agent
to file appropriately complete Code financing statements naming such person or entity as debtor and Agent as secured party, and describing
the Collateral, and agrees to execute and deliver such other documentation as Agent (or its successors or assigns) may require to evidence,
protect and perfect the Liens created by the Guarantee and Collateral Agreement, as modified hereby.

 

4.
Each such Person’s address and fax number for notices under the Guarantee and Collateral Agreement shall be that of Borrower as
set forth in the Guarantee and Collateral Agreement.

 

5.
This Agreement shall be deemed to be part of, and a modification to, the Guarantee and Collateral Agreement and shall be governed by
all the terms and provisions of the Guarantee and Collateral Agreement, with respect to the modifications intended to be made to such
agreement, which terms are incorporated herein by reference, are ratified and confirmed and shall continue in full force and effect as
valid and binding agreements of each such person or entity enforceable against such person or entity. Each such person or entity hereby
waives notice of Agent’s acceptance of this Agreement. Each such person or entity will deliver an executed original of this Agreement
to Agent.

 

[add
signature block for each new Grantor and an acknowledgement by each existing Grantor]

 

    	[Annex I] 
	Guarantee and Collateral Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]